US8435968B2 - Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use - Google Patents

Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use Download PDF

Info

Publication number
US8435968B2
US8435968B2 US13/063,956 US200913063956A US8435968B2 US 8435968 B2 US8435968 B2 US 8435968B2 US 200913063956 A US200913063956 A US 200913063956A US 8435968 B2 US8435968 B2 US 8435968B2
Authority
US
United States
Prior art keywords
independently
present
compound according
saturated aliphatic
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US13/063,956
Other languages
English (en)
Other versions
US20110172189A1 (en
Inventor
Iain Robert Greig
Rose Mary Sheridan
Raymond Fisher
Matthew John Tozer
Juha Andrew Clase
Andrew Smith
Andrew Robert Tuffnell
Robert Jurgen Van 'T Hof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pimco 2664 Ltd
Original Assignee
Pimco 2664 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimco 2664 Ltd filed Critical Pimco 2664 Ltd
Priority to US13/063,956 priority Critical patent/US8435968B2/en
Assigned to PIMCO 2664 LIMITED reassignment PIMCO 2664 LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHERIDAN, ROSE MARY, GREIG, IAIN ROBERT, CLASE, JUHA ANDREW, VAN 'T HOF, ROBERT JURGEN, FISHER, RAYMOND, SMITH, ANDREW, TOZER, MATTHEW JOHN, TUFFNELL, ANDREW ROBERT
Publication of US20110172189A1 publication Critical patent/US20110172189A1/en
Application granted granted Critical
Publication of US8435968B2 publication Critical patent/US8435968B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Definitions

  • PCT/GB2009/002221 is a non-provisional application of U.S. provisional patent application No. 61/098,271 filed Sep. 19, 2008 and United Kingdom patent application number 0817207.4 filed Sep. 19, 2008, the contents of each of which are incorporated herein by reference in their entirety.
  • the present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds (collectively referred to herein as “APSAC compounds”).
  • APSAC compounds aryl-phenyl-sulfonamido-cycloalkyl compounds
  • the present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in r
  • Ranges are often expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of the antecedent “about,” it will be understood that the particular value forms another embodiment.
  • RA Rheumatoid arthritis
  • RA is a chronic inflammatory disease characterised by painful swelling, stiffness, loss of movement and the destruction of cartilage and bone.
  • RA is characterised by an inflammation of the synovial lining of multiple joints and commonly affects the joints of the wrist and hands and may also affect the elbows, shoulders, hips, neck and knees; the ultimate hallmark of RA is joint destruction.
  • RA is a common disease, estimated to affect up to 1% of adults in the developed world, with women more than twice as likely to be affected and over 30% of patients likely to become severely disabled within 20 years (see, e.g., Feldmann et al., 2006).
  • RA is one of the most important causes of disability in the western world and is associated with a significant reduction in quality of life as well as increased mortality if left untreated. The disease can start at any age, with individuals aged between 40 and 70 most commonly affected.
  • rheumatoid factor antibodies to the Fc fragment of IgG, known as rheumatoid factor, are present in 60-80% of adults with RA (see, e.g., Weissmann et al, 2006) but it is not known whether this factor is responsible for initiating the inflammatory cascade or is generated at a later stage and propagates the process (see, e.g., Weissmann et al, 2006); there is also a notable genetic predisposition to the disease, as shown by the presence of HLA-DR4 antibody in 70% of patients (see, e.g., Klareskog et al, 2006).
  • RA RA-induced RA
  • T-cells infiltrating the synovial membrane lining the affected joint; this then leads to the activation of macrophages, monocytes and synovial fibroblasts (see, e.g., Firestein, 1996) by way of cell-cell contact and release of various cytokines, including TNF ⁇ and IL-1 (see, e.g., Feldmann, 1996).
  • cytokines including TNF ⁇ and IL-1
  • Activation of these cells leads to the overproduction of a range of pro-inflammatory cytokines, of which the most important are TNF ⁇ , IL-1 and IL-6 (see, e.g., Brennan et al, 1996; McInnes et al, 2005).
  • pro-inflammatory cytokines are then instrumental in orchestrating several complex signal transduction cascades, including the NF ⁇ B, MAPK and Jak/STAT pathways (see, e.g., Firestein et al, 1999) which lead to the induction of genes coding for various products that propagate the inflammatory response and also promote tissue destruction.
  • tissue-degrading enzymes such as collagenases, matrix metalloproteases, cathepsins, and other pro-inflammatory factors such as selectins, integrins, leukotrienes, prostaglandins, chemokines, and other cytokines.
  • TNF ⁇ and IL-1 also induce RANKL expression.
  • RANKL is an essential factor for the generation of osteoclasts (see, e.g., Tanaka et al, 2003; Roodman, 2006), and upregulated RANKL-production leads to increased osteoclast differentiation and ultimately bone destruction (see, e.g., Tanaka et al, 2003; Roodman, 2006).
  • the inflammatory response leads to the accumulation of many leukocytes and immune factor populations within the affected joint and also to hyperplasia of the Type-A and Type-B synoviocytes (see, e.g., Firestein et al, 2005), leading to thickening and vascularisation of the synovium into a destructive and aggressive tissue known as a pannus.
  • the pannus contains both osteoclasts, which destroy bone, and metalloproteases, which continue the destruction of cartilage.
  • RA RA-modifying anti-rheumatic drugs
  • drugs include a number of older drugs, including gold salts; sulfasalazine; antimalarials such as hydroxychloroquine; D-penicillamine; immunosuppressants such as mycophenolic acid, azathioprine, cyclosporine A, tacrolimus and sirolimus; minocycline; leflunomide; and most importantly, methotrexate (see, e.g., Smolen et al, 2003).
  • Methotrexate is now the gold-standard therapy for clinical trial comparisons, and is generally used in combination with newer therapies. It is effective in most patients but, in common with all of the above agents, has significant gastrointestinal side effects, which lead to roughly 50% of patients eventually having to cease treatment with methotrexate (see, e.g., Mount et al, 2005).
  • a further drawback of these older DMARDs is the length of time taken for the drug to start acting, ranging from weeks with methoxtrexate, to months with gold salts. Whilst full remissions only occur in about a quarter of patients, for those showing no effect it is not generally possible to stop therapy without suffering the risk of a more violent disease rebound (see, e.g., Smolen et al, 2003).
  • anti-TNF anti-tumour necrosis factor
  • TNF ⁇ production within the joint may in fact play the pivotal role in orchestrating the production of other factors which leads to the persistence of inflammation and tissue damage (see, e.g., Feldmann et al, 2001; Brennan et al, 1999; Brennan, 1992).
  • TNF ⁇ TNF ⁇ -independent effects of IL-1 in RA, most notably bone destruction (see, e.g., van den Berg et al, 1999; van den Berg et al, 2002).
  • TNF ⁇ is a cytokine that effects many different functions, including the alteration of tissue remodelling, changes to the permeability of the epithelial cell barrier, activation of macrophages, up-regulation of adhesion molecules, recruitment of other immune response effectors and, most importantly in RA, it instigates the signalling cascade which leads to the activation of the transcription factors NF ⁇ B and AP-1 (see, e.g., Liu, 2005; Baud et al, 1999). Binding of TNF ⁇ and IL-1 to their respective receptors leads to the recruitment of downstream signal transducers called TRAFs.
  • I ⁇ B is the inhibitor of NF ⁇ B, which acts by preventing translocation of NF ⁇ B to the nucleus. Phosphorylation of I ⁇ B by I ⁇ B kinase leads to degradation of I ⁇ B. Once I ⁇ B has been degraded, NF ⁇ B migrates to the nucleus, where it promotes transcription of anti-apoptotic genes, which promote survival of T and B-cells, thereby prolonging the immune response. This prolongation of the inflammatory response is central to the chronic nature of RA. The importance of NF ⁇ B activation is demonstrated by the fact that inhibition of NF ⁇ B activity by inhibitory peptides can prevent arthritis in animal models of RA (see, e.g., Jimi et al, 2004).
  • Anti-TNF ⁇ therapy represents the market-leading therapies for RA, and is performed either with neutralizing antibodies such as infliximab (Remicade® J&J and Schering Plough) and adalimumab (Humira®, Abbott) or decoy receptors such as etanercept (Enbrel® Amgen and Wyeth), both which represent validated and highly effective treatments for RA.
  • Anti-TNF ⁇ biologicals are already licensed for RA, Crohn's disease, and psoriasis. A number of other inflammatory and autoimmune disorders are also being investigated as potential targets.
  • TNF ⁇ tumor necrosis factor ⁇
  • Cimzia® pegylated anti-TNF ⁇ fragment certolizumab
  • TACE TNF ⁇ converting enzyme
  • metalloproteases responsible for cleaving TNF ⁇ from the cell surface see, e.g., Smolen et al, 2003; Mount et al, 2005.
  • TNF ⁇ inflammatory bowel disease
  • IBD inflammatory bowel disease
  • psoriasis inflammatory bowel disease
  • IBD ulcerative colitis
  • CD Crohn's disease
  • Psoriasis is an inflammatory response of the skin affecting 1-3% of the population in the western world.
  • the disease is characterised by raised, red, scaly plaques on the skin, which may be itchy and also cause significant psychological distress by their unsightly nature.
  • a further complication of psoriasis is the development of psoriatic arthritis, an inflammatory arthritis of the joints, in up to 40% of patients, which develops on average 10 years after the first symptoms of skin disease are seen (see, e.g., Gottling, 2005).
  • IBD and psoriasis are unknown and may involve a complex combination of infectious agents, environmental, and genetic factors, generating an inappropriate and prolonged inflammatory response.
  • IBD and psoriasis Treatment of IBD and psoriasis has followed a similar pattern to that of RA, with the past use of immunoregulatory agents such as NSAIDs, methotrexate, cyclosporine, steroids, and antimetabolites such as 6-mercaptopurine for IBD (see, e.g., Korzenik et al, 2006) and methotrexate and cyclosporine for psoriasis (see, e.g., Gottlieb, 2005).
  • the treatment of both has been revolutionized by the advent of biological agents, in particular those which block TNF ⁇ signalling.
  • Etanercept is licensed for the treatment of psoriasis and psoriatic arthritis; both infliximab and adalimumab are licensed for psoriatic arthritis, IBD, and psoriasis.
  • Apoptosis (programmed cell death) plays a key role in the removal of abnormal cells; defects in the signalling cascades, which would normally lead to its induction, play a key role in oncogenesis. Radiotherapy and many chemotherapeutic agents act by causing cellular damage, which would normally induce apoptosis; defects in the pathway will therefore also reduce the effectiveness of such agents.
  • the most important effector molecules in the signalling pathway leading to apoptosis are known as the caspases, which may be triggered by a number of stimuli, including TNF ⁇ binding to its receptor.
  • Osteoporosis is a common disease characterised by reduced bone density, deterioration of bone tissue, and an increased risk of fracture. Many factors contribute to the pathogenesis of osteoporosis including poor diet, lack of exercise, smoking, and excessive alcohol intake. Osteoporosis may also arise in association with inflammatory diseases such as rheumatoid arthritis, endocrine diseases such as thyrotoxicosis, and with certain drug treatments such as treatment with glucocorticoids. However one of the most important factors in the pathogenesis of osteoporosis is heredity.
  • Paget's disease of bone is a common condition of unknown cause, characterised by increased bone turnover and disorganised bone remodelling, with areas of increased osteoclastic and osteoblast activity.
  • Pagetic bone is often denser than normal, the abnormal architecture causes the bone to be mechanically weak, resulting in bone deformity and increased susceptibility to pathological fracture.
  • Cancer-associated bone disease can be manifest by the occurrence of hypercalcemia or the development of osteolytic and/or osteosclerotic metastases. Increased osteoclastic bone resorption plays a key role in the pathogenesis of both conditions. Whilst almost any cancer can be complicated by bone metastases, the most common sources are multiple myeloma, breast carcinoma, and prostate carcinoma. The most common tumours associated with hypercalcemia are multiple myeloma, breast carcinoma, and lung carcinoma.
  • RANKL signalling has been shown to play a major role in osteoclast over-activity and a consequent increase in bone loss (see, e.g., Tanaka et al, 2003; Roodman, 2006).
  • the use of drugs which affect this pathway has been validated by the completion of clinical trials of the monoclonal antibody against RANKL AMG-162 (Denosumab® Amgen) for the treatment of osteoporosis/multiple myeloma.
  • bone loss also plays a major role in the pathophysiology of rheumatoid arthritis and drugs which prevent activation of the signalling pathways described (e.g. TNF ⁇ blockers) are also able to prevent this bone loss.
  • drugs which prevent activation of the signalling pathways described e.g. TNF ⁇ blockers
  • the inventors have identified a new class of compounds which, for example, prevent inflammation and/or bone loss, and thus may be used in the treatment of diseases with an inflammatory or autoimmune component, including, for example, rheumatoid arthritis, inflammatory bowel disease, psoriasis, and psoriatic arthritis; diseases which involve bone loss, including, for example, bone loss associated with rheumatoid arthritis, osteoporosis, Paget's disease of bone, and multiple myeloma; as well as cancer associated with activation of NF ⁇ B, with aberrant NF ⁇ B signaling, or with inflammation, including haematological malignancies such as multiple myeloma, leukaemia, T-cell lymphoblastic lymphoma, and other lymphoma (e.g., non-Hodgkin Lymphoma), and solid tumours such as cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain
  • this action may be via a mechanism that involves blocking TNF ⁇ and/or IL-1 and/or RANKL-signalling.
  • Greig et al., 2004 and Greig et al., 2006 describe a class of biphenyl alkyl sulfonamides as anti-resorptive agents for the treatment of bone diseases, including, for example, 2′,4′-difluoro-biphenyl-4-sulfonic acid (5-hydroxy-pentyl)-amide (ABD248) and 2′,4′-difluoro-biphenyl-4-sulfonic acid (4-hydroxy-butyl)-amide (ABD256) (shown below).
  • the present inventors have identified a new a class of aryl sulfonamides, as defined herein, that have surprising and unexpected properties.
  • the present inventors have identified a new a class of aryl sulfonamides, as defined herein, that have, inter alia, one or more surprising and unexpected properties.
  • the inventors believe that the new compounds have been protected against the major route of metabolism acting upon the previous biphenyl aryl sulfonamides (specifically, oxidation of the terminal alcohol to give a carboxylic acid) by the replacement of the aryl ring with a carbocyclic group; this may also be further combined with replacement of the alcohol by an amine.
  • these replacement groups have also been selected to provide a further substantial enhancement in the aqueous solubility of the compounds. If a drug is to show oral activity, it must first be solvated, to permit absorption from the gastrointestinal tract. Second, the drug must be sufficiently resistant to first-pass metabolism by metabolic enzymes contained within the liver so as to be able to enter the circulation and permit sufficient quantities to reach the biological target. Third, the drug must be sufficiently potent against the biological target to give the desired therapeutic effect.
  • the optimization of pharmacokinetic properties (action of the body on the drug) of a drug is a developmental barrier of equal challenge as compared to the optimization of pharmacodynamic properties (action of the drug on the body).
  • the new compounds disclosed herein show substantial improvements in their properties as oral therapeutic agents, as compared to previous compounds identified above.
  • the new compounds combine the characteristics required of orally active agents for the treatment of inflammatory diseases and/or for the treatment of bone loss.
  • One aspect of the invention pertains to certain aryl-phenyl-sulfonamido-cycloalkyl compounds (for convenience, collectively referred to herein as “APSAC compounds”), as described herein.
  • APSAC compounds aryl-phenyl-sulfonamido-cycloalkyl compounds
  • compositions e.g., a pharmaceutical composition
  • a composition comprising an APSAC compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising the step of admixing an APSAC compound, as described herein, and a pharmaceutically acceptable carrier or diluent.
  • Another aspect of the invention pertains to a method of inhibiting an inflammatory response, in vitro or in vivo, comprising contacting an immune system component with an effective amount of an APSAC compound, as described herein.
  • Another aspect of the invention pertains to a method of inhibiting cellular and/or molecular pathways leading to joint destruction, in vitro or in vivo, comprising contacting cells associated with an immune response with a therapeutically-effective amount of an APSAC compound, as described herein.
  • Another aspect of the invention pertains to a method of inhibiting osteoclast survival, formation, and/or activity, in vitro or in vivo, comprising contacting an osteoclast with an effective amount of an APSAC compound, as described herein.
  • Another aspect of the invention pertains to a method of inhibiting bone resorption, in vitro or in vivo, comprising contacting cells in the bone microenvironment with a therapeutically-effective amount of an APSAC compound, as described herein.
  • Another aspect of the present invention pertains to a method of treatment comprising administering to a subject in need of treatment a therapeutically-effective amount of an APSAC compound, as described herein, preferably in the form of a pharmaceutical composition.
  • Another aspect of the present invention pertains to an APSAC compound as described herein for use in a method of treatment of the human or animal body by therapy.
  • Another aspect of the present invention pertains to use of an APSAC compound, as described herein, in the manufacture of a medicament for use in treatment.
  • the treatment is treatment of inflammation and/or joint destruction and/or bone loss.
  • the treatment is treatment of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system.
  • the treatment is treatment of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • inflammatory and autoimmune disorders for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • the treatment is treatment of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • inflammatory and autoimmune disorders for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • the treatment is treatment of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like.
  • the treatment is treatment of a haematological malignancy, e.g., multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma), e.g., a haematological malignancy, multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma) associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a haematological malignancy e.g., multiple myeloma, leukaemia, or lymphoma
  • a haematological malignancy e.g., multiple myeloma, leukaemia, or lymphoma
  • NF ⁇ B e.g., non-Hodgkin Lymphoma
  • inflammation
  • the treatment is treatment of a solid tumour cancer, e.g., cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, or melanoma, e.g., a solid tumour cancer, cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, and melanoma associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a solid tumour cancer e.g., cancer of the bladder, breast cancer (female and/or male)
  • colon cancer e.g., cancer of the bladder, breast cancer (female and/or male
  • colon cancer e.g., a solid tumour cancer, cancer of the bladder, breast cancer
  • the treatment is treatment of a haematological malignancy, e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia, e.g., a haematological malignancy, T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a haematological malignancy e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • the treatment is treatment of a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer, or basal cell ameloblastoma, e.g., a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer, or basal cell ameloblastoma associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a solid tumour cancer e.g., renal cell carcinoma, breast cancer (female and/or male)
  • gastric cancer e.g., prostate cancer, colon cancer
  • basal cell ameloblastoma associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and
  • the treatment is part of treatment by combination therapy, e.g., in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • kits comprising (a) an APSAC compound, as described herein, preferably provided as a pharmaceutical composition and in a suitable container and/or with suitable packaging; and (b) instructions for use, for example, written instructions on how to administer the compound.
  • Another aspect of the present invention pertains to an APSAC compound obtainable by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
  • Another aspect of the present invention pertains to an APSAC compound obtained by a method of synthesis as described herein, or a method comprising a method of synthesis as described herein.
  • Another aspect of the present invention pertains to novel intermediates, as described herein, which are suitable for use in the methods of synthesis described herein.
  • Another aspect of the present invention pertains to the use of such novel intermediates, as described herein, in the methods of synthesis described herein.
  • FIG. 1 is a graph showing mean plasma concentration (ng/mL) of the APSAC compound ABD773 ( ⁇ ) after oral administration (1 mg/kg) to a rat model.
  • FIG. 2 is a graph showing mean plasma concentration (ng/mL) of the APSAC compound ABD773 ( ⁇ ) after intravenous administration (1 mg/kg) to a rat model.
  • FIG. 3 is a graph showing mean plasma concentration (ng/mL) of the APSAC compound ABD781 ( ⁇ ) after oral administration (1 mg/kg) to a rat model.
  • FIG. 4 is a graph showing mean plasma concentration (ng/mL) of the APSAC compound ABD781 ( ⁇ ) after intravenous administration (1 mg/kg) to a rat model.
  • FIG. 5 is a graph showing mean plasma concentration ( ⁇ g/mL) of the reference compound ABD455 ( ⁇ ) after oral administration (2.5 mg/kg) to a rat model.
  • FIG. 6 is a graph showing mean plasma concentration ( ⁇ g/mL) of the reference compound ABD455 ( ⁇ ) after intravenous administration (2.5 mg/kg) to a rat model.
  • FIG. 7 is a series of images of human monocytes monitored using fluorescent light microscopy and showing the effects of ABD599 and ABD781 on caspase 3 activation in the presence of TNF ⁇ : (a) TNF ⁇ alone; (b) TNF ⁇ with 10 ⁇ M ABD599, and (c) TNF ⁇ with 10 ⁇ M ABD781.
  • the compounds of the present invention are structurally related to 1-(aryl)-phenyl-4-sulfonic acid cyclohexyl amide:
  • aryl-phenyl-sulfonamido-cycloalkyl or “APSAC compounds”.
  • -A is independently:
  • —Ar is independently phenyl, pyridinyl, or pyrimidinyl.
  • —Ar is independently phenyl.
  • —Ar is independently pyridinyl.
  • —Ar is independently pyridin-2-yl.
  • —Ar is independently pyridin-3-yl.
  • —Ar is independently pyridin-4-yl.
  • —Ar is independently pyrimidinyl.
  • —Ar is independently pyrimidin-2-yl.
  • —Ar is independently pyrimidin-4-yl.
  • —Ar is independently pyrimidin-5-yl.
  • p is independently an integer from 0 to 3.
  • p is independently an integer from 1 to 3.
  • p is independently 0.
  • p is independently 1.
  • p is independently 2.
  • p is independently 3.
  • -A is independently:
  • -A is independently:
  • -A is independently:
  • -A is independently:
  • the Group -A Phenyl and Pyridinyl: the Groups ⁇ W— and —Y ⁇
  • ⁇ W— is —CH ⁇ or —CR W ⁇ and —Y ⁇ is —CH ⁇ or —CR Y ⁇ .
  • ⁇ W— is —CH ⁇ and —Y ⁇ is —CH ⁇ , as in, for example:
  • ⁇ W— is —CH ⁇ or —CR W ⁇ and —Y ⁇ is —N ⁇ .
  • ⁇ W— is —CH ⁇ and —Y ⁇ is —N ⁇ , as in, for example:
  • ⁇ W— is —N ⁇ and —Y ⁇ is —CH ⁇ or —CR Y ⁇ .
  • ⁇ W— is —N ⁇ and —Y ⁇ is —CH ⁇ , as in, for example:
  • —R W if present, is independently saturated aliphatic C 1-4 alkyl.
  • —R W if present, is independently -Me.
  • —R Y if present, is independently saturated aliphatic C 1-4 alkyl.
  • —R Y if present, is independently -Me.
  • -A is independently:
  • —R X2 if present, is independently —H or —R X2S .
  • —R X2 if present, is independently —R X2S .
  • —R X2 if present, is independently —H.
  • —R X3 if present, is independently —H or —R X3S .
  • —R X3 if present, is independently —R X3S .
  • —R X3 if present, is independently —H.
  • —R X4 if present, is independently —H or —R X4S .
  • —R X4 if present, is independently —R X4S .
  • —R X4 if present, is independently —H.
  • the leading phenylene group is the phenylene group that links the group -A, on the left, with the group —S( ⁇ O) 2 N(R S N)(DQ), on the right.
  • the leading phenylene group is:
  • q is independently an integer from 0 to 3.
  • q is independently an integer from 1 to 3.
  • q is independently 0.
  • q is independently 1.
  • q is independently 2.
  • leading phenylene group is:
  • each —R X is independently:
  • each —R X is independently:
  • each —R X is independently —F, —Cl, —Br, —I, —R XX , —OH, —OR XX , —SR XX , —CF 3 , —OCF 3 , —SCF 3 , —C( ⁇ O)R XX , —CN, or —NO 2 .
  • each —R X is independently —F, —Cl, —Br, —I, —R XX , —OH, —OR XX , —SR XX , —CF 3 , —OCF 3 , —SCF 3 , —CN, or —NO 2 .
  • each —R X is independently —F, —Cl, —Br, —I, —R XX , —OH, —OR XX , —SR XX , —CF 3 , —OCF 3 , —CN, or —NO 2 .
  • each —R X is independently —F, —Cl, —Br, —I, —R XX , —OR XX , —SR XX , —CF 3 , or —OCF 3 .
  • each —R XX is independently saturated aliphatic C 1-6 alkyl, phenyl, or benzyl.
  • each —R XX is independently saturated aliphatic C 1-6 alkyl.
  • each —R XX is independently saturated aliphatic C 1-4 alkyl.
  • —NR YY R ZZ is independently pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, or morpholino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR YY R ZZ is independently pyrrolidino, piperidino, piperazino, or morpholino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • leading phenylene group is:
  • each —R XCC if present, is independently —F, —Cl, or —R XCCC .
  • each —R XCC if present, is independently —R XCCC .
  • each —R XCCC is independently -Me, -Et, -nPr, or -iPr.
  • each —R XCCC if present, is independently -Me or -Et.
  • —R X2S if present, is independently —R X .
  • —R X2S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —SR XA , —CF 3 , or —OCF 3 , wherein each —R XA is independently saturated aliphatic C 1-4 alkyl.
  • —R X2S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —CF 3 , or —OCF 3 .
  • —R X2S if present, is independently —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 .
  • —R X2S if present, is independently —F, —Cl, or —CF 3 .
  • —R X2S if present, is independently —F or —Cl.
  • —R X2S if present, is independently —F.
  • —R X2S if present, is independently —Cl.
  • —R X3S if present, is independently —R X .
  • —R X3S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —SR XA , —CF 3 , or —OCF 3 , wherein each —R XA is independently saturated aliphatic C 1-4 alkyl.
  • —R X3S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —CF 3 , or —OCF 3 .
  • —R X3S if present, is independently —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 .
  • —R X3S if present, is independently —F, —Cl, or —CF 3 .
  • —R X3S if present, is independently —F or —Cl.
  • —R X3S if present, is independently —F.
  • —R X3S if present, is independently —Cl.
  • —R X4S if present, is independently —R X .
  • —R X4S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —SR XA , —CF 3 , or —OCF 3 , wherein each —R XA is independently saturated aliphatic C 1-4 alkyl.
  • —R X4S if present, is independently —F, —Cl, —Br, —I, —R XA , —OR XA , —CF 3 , or —OCF 3 .
  • —R X4S if present, is independently —F, —Cl, —Br, —I, —CF 3 , or —OCF 3 .
  • —R X4S if present, is independently —F, —Cl, or —CF 3 .
  • —R X4S if present, is independently —F or —Cl.
  • —R X4S if present, is independently —F.
  • —R X4S if present, is independently —Cl.
  • —R X2S and —R X4S are each independently —F.
  • —R X2S and —R X4S are each independently —Cl.
  • each —R XA is independently saturated aliphatic C 1-4 alkyl.
  • each —R XA if present, is independently -Me or -Et.
  • each —R XA if present, is independently -Me.
  • -DQ is independently -D 1 -Q 1 .
  • -D 1 - is independently cyclopentane-di-yl, cyclohexane-di-yl, cycloheptane-di-yl, bicyclo[3.1.1]heptane-di-yl, or bicyclo[3.2.1]octane-di-yl, and is optionally substituted with one or more groups —R D .
  • -D 1 - is independently cyclopentane-di-yl, cyclohexane-di-yl, or cycloheptane-di-yl, and is optionally substituted with one or more groups —R D .
  • -D 1 - is independently cyclopentane-di-yl, cyclohexane-di-yl, cycloheptane-di-yl, bicyclo[3.1.1]heptane-di-yl, or bicyclo[3.2.1]octane-di-yl.
  • -D 1 - is independently cyclopentane-di-yl, cyclohexane-di-yl, or cycloheptane-di-yl.
  • -D 1 - is independently cyclopentane-di-yl or cyclohexane-di-yl.
  • -D 1 - is independently cyclopentane-di-yl.
  • -D 1 - is independently cyclopentane-1,2-di-yl.
  • -D 1 - is independently cyclopentane-1,3-di-yl.
  • -D 1 - is independently cyclohexane-di-yl.
  • -D 1 - is independently cyclohexane-1,2-di-yl.
  • -D 1 - is independently cyclohexane-1,3-di-yl.
  • -D 1 - is independently cyclohexane-1,4-di-yl.
  • -D 1 - is independently cycloheptane-di-yl.
  • -D 1 - is independently cycloheptane-1,2-di-yl.
  • -D 1 - is independently cycloheptane-1,3-di-yl.
  • -D 1 - is independently cycloheptane-1,4-di-yl.
  • -D 1 - is independently cyclopentane-1,2-di-yl, cyclopentane-1,3-di-yl, cyclohexane-1,3-di-yl, cyclohexane-1,4-di-yl, or cycloheptane-1,4-di-yl.
  • -D 1 - is independently cyclopentane-1,2-di-yl, cyclopentane-1,3-di-yl, or cyclohexane-1,4-di-yl.
  • -D 1 - is independently bicyclo[3.2.1]octane-di-yl.
  • -D 1 - is independently bicyclo[3.2.1]octane-3,8-di-yl.
  • -D 1 - is independently bicyclo[3.2.1]octane-8,3-di-yl.
  • -D 1 - is independently bicyclo[3.1.1]heptane-di-yl.
  • -D 1 - is independently bicyclo[3.1.1]heptane-3,6-di-yl.
  • -D 1 - is independently bicyclo[3.1.1]heptane-6,3-di-yl.
  • -D 2 , if present, is independently cyclopentane-yl-ylidene, cyclohexane-yl-ylidene, cycloheptane-yl-ylidene, bicyclo[3.1.1]heptane-yl-ylidene, or bicyclo[3.2.1]octane-yl-ylidene, and is optionally substituted with one or more groups —R D .
  • -D 2 , if present, is independently cyclopentane-yl-ylidene, cyclohexane-yl-ylidene, cycloheptane-yl-ylidene, bicyclo[3.1.1]heptane-yl-ylidene, or bicyclo[3.2.1]octane-yl-ylidene.
  • -D 2 , if present, is independently cyclopentane-yl-ylidene, cyclohexane-yl-ylidene, or cycloheptane-yl-ylidene, and is optionally substituted with one or more groups —R D .
  • -D 2 , if present, is independently cyclopentane-yl-ylidene, cyclohexane-yl-ylidene, or cycloheptane-yl-ylidene.
  • -D 2 , if present, is independently cyclopentane-yl-ylidene or cyclohexane-yl-ylidene.
  • -D 2 , if present, is independently cyclopentane-yl-ylidene.
  • -D 2 , if present, is independently cyclopentane-1-yl-2-ylidine.
  • -D 2 , if present, is independently cyclopentane-1-yl-3-ylidine.
  • -D 2 , if present, is independently cyclohexane-yl-ylidene.
  • -D 2 , if present, is independently cyclohexane-1-yl-2-ylidine.
  • -D 2 , if present, is independently cyclohexane-1-yl-3-ylidine.
  • -D 2 , if present, is independently cyclohexane-1-yl-4-ylidine.
  • -D 2 , if present, is independently cycloheptane-yl-ylidene.
  • -D 2 , if present, is independently cycloheptane-1-yl-2-ylidine.
  • -D 2 , if present, is independently cycloheptane-1-yl-3-ylidine.
  • -D 2 , if present, is independently cycloheptane-1-yl-4-ylidine.
  • -D 2 , if present, is independently bicyclo[3.2.1]octane-yl-ylidene.
  • -D 2 , if present, is independently bicyclo[3.2.1]octane-3-yl-8-ylidene.
  • -D 2 , if present, is independently bicyclo[3.2.1]octane-8-yl-3-ylidene.
  • -D 2 , if present, is independently bicyclo[3.1.1]heptane-yl-ylidene.
  • -D 2 , if present, is independently bicyclo[3.1.1]heptane-3-yl-6-ylidene.
  • -D 2 , if present, is independently bicyclo[3.1.1]heptane-6-yl-3-ylidene.
  • each —R D is independently selected from —F, —Cl, —Br, —I, —R DD , —CF 3 , —OH, —OR DD , —NH 2 , —NHR DD , and —NR DD 2 , wherein each —R DD is independently saturated aliphatic C 1-4 alkyl.
  • each —R DD if present, is independently -Me or -Et.
  • each —R DD if present, is independently -Me.
  • -D 1 - is independently 4-methyl-cyclohexane-1,4-di-yl.
  • -Q 1 is independently selected from:
  • -Q 1 is independently selected from:
  • -Q 1 is independently:
  • -Q 1 is independently:
  • -Q 1 is independently selected from:
  • -Q 1 is independently selected from:
  • -Q 1 is independently:
  • -Q 1 is independently:
  • -Q 1 is independently:
  • -Q 1 is independently selected from:
  • -Q 1 is independently selected from:
  • -Q 1 is independently:
  • -Q 1 is independently:
  • -Q 1 is independently:
  • —NR 1N R 2N is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino, or diazepino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR 1N R 2N is independently pyrrolidino, piperidino, piperazino, or morpholino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR 1N R 2N is independently piperidino, piperazino, or morpholino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR 1N R 2N if present, is independently pyrrolidino or morpholino.
  • —NR 1N R 2N if present, is independently morpholino.
  • each —R CN if present, is independently -Me or -Et.
  • each —R CN if present, is independently -Me.
  • each —R CF if present, is independently —CF 3 , —CH 2 CF 3 , or —CH 2 CH 2 F.
  • each —R CF if present, is independently —CF 3 .
  • —NR 1N R 2N is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NMeEt, —NH(iPr), —NH(CH 2 CF 3 ), pyrrolidino, or morpholino.
  • —NR 1N R 2N is independently —NH 2 , —NHMe, —NMe 2 , or morpholino.
  • —R 1A and —R 2A together form a saturated aliphatic C 2-4 alkylene group.
  • —R 1A and —R 2A together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 1A and —R 2A together form —CH 2 CH 2 —.
  • —R 1B and —R 2B together form a saturated aliphatic C 2-4 alkylene group.
  • —R 1B and —R 2B together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 1B and —R 2B together form —CH 2 CH 2 —.
  • —R 1B and —R 2B together form ⁇ O.
  • —R 3A if present, is independently —H, —R C , or —R F ;
  • —R 3A and —R 4A together form a saturated aliphatic C 2-4 alkylene group.
  • —R 3A and —R 4A together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 3A and —R 4A together form —CH 2 CH 2 —.
  • —R 5A and —R 6A together form a saturated aliphatic C 2-4 alkylene group.
  • —R 5A and —R 6A together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 5A and —R 6A together form —CH 2 CH 2 —.
  • —R 3B and —R 4B together form a saturated aliphatic C 2-4 alkylene group.
  • —R 3B and —R 4B together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 3B and —R 4B together form —CH 2 CH 2 —.
  • —R 5B and —R 6B together form a saturated aliphatic C 2-4 alkylene group.
  • —R 5B and —R 6B together form —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, or —CH 2 CH 2 CH 2 CH 2 —.
  • —R 5B and —R 6B together form —CH 2 CH 2 —.
  • —R O if present, is independently saturated aliphatic C 1-4 alkyl.
  • —R O if present, is independently -Me or -Et.
  • —R O if present, is independently -Me.
  • each —R C if present, is independently saturated aliphatic C 1-4 alkyl.
  • each —R C if present, is independently -Me or -Et.
  • each —R C if present, is independently -Me.
  • each —R F is independently saturated aliphatic C 1-4 fluoroalkyl.
  • each —R F if present, is independently —CF 3 , —CH 2 CF 3 , or —CH 2 CH 2 F.
  • each —R F if present, is independently —CF 3 .
  • —R J if present, is independently —NH 2 , —NHR JN1 , —NR JN1 2 , or —NR JN2 R JN3 .
  • —R J if present, is independently —NH 2 , —NHR JN1 , or —NR JN1 2 .
  • —R J if present, is independently —NH 2 .
  • —R J if present, is independently —NHR JN1 .
  • —R J if present, is independently —NR JN1 2 .
  • —R J if present, is independently —NR JN2 R JN3 .
  • each —R JN1 if present, is independently saturated aliphatic C 1-4 alkyl.
  • each —R JN1 is independently -Me, -Et, or -iPr.
  • each —R JN1 if present, is independently -Me or -Et.
  • each —R JN1 if present, is independently -Me.
  • —NR JN2 R JN3 is independently azetidino, pyrrolidino, imidazolidino, pyrazolidino, piperidino, piperazino, morpholino, thiomorpholino, azepino, or diazepino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR JN2 R JN3 is independently piperidino, piperazino, or morpholino, each optionally substituted with one or more groups independently selected from saturated aliphatic C 1-4 alkyl.
  • —NR JN2 R JN3 if present, is independently morpholino.
  • —R J is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NH(nPr), —N(nPr) 2 , —NH(iPr), —N(iPr) 2 , piperidino, piperazino, or morpholino.
  • —R J if present, is independently —NH 2 , —NHMe, —NMe 2 , or morpholino.
  • —R J if present, is independently —NH 2 , —NHMe, or —NMe 2 .
  • the Group -Q 1 Some Preferred Embodiments
  • -Q 1 is independently —OH, —CH 2 OH, —CH(Me)OH, —C(Me) 2 OH, —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NMeEt, —NH(iPr), pyrrolidino, morpholino, —NHCH 2 CF 3 , —CH 2 NH 2 , —CH 2 NHMe, —CH 2 NMe 2 , —CH 2 NHEt, —CH 2 NEt 2 , —CH(NHMe)CH 2 OH, —C( ⁇ O)NH 2 , —C( ⁇ O)NHMe, —C( ⁇ O)NMe 2 , —C( ⁇ O)NHEt, or —C( ⁇ O)NEt 2 .
  • -Q 1 is independently —OH, —CH 2 OH, —CH(Me)OH, —C(Me) 2 OH, —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , or —CH(NHMe)CH 2 OH.
  • -Q 1 is independently —OH, —CH 2 OH, —CH(Me)OH, or —C(Me) 2 OH.
  • -Q 1 if present, is independently —OH.
  • -Q 1 is independently —CH 2 OH, —CH(Me)OH, or —C(Me) 2 OH.
  • -Q 1 if present, is independently —CH 2 OH.
  • -Q 1 is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NMeEt, —NH(iPr), pyrrolidino, morpholino, —NHCH 2 CF 3 , —CH 2 NH 2 , —CH 2 NHMe, —CH 2 NMe 2 , —CH 2 NHEt, —CH 2 NEt 2 , —CH(NHMe)CH 2 OH, —C( ⁇ O)NH 2 , —C( ⁇ O)NHMe, —C( ⁇ O)NMe 2 , —C( ⁇ O)NHEt, or —C( ⁇ O)NEt 2 .
  • -Q 1 is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NMeEt, —NH(iPr), pyrrolidino, morpholino, —NHCH 2 CF 3 , —CH 2 NH 2 , —CH 2 NHMe, —CH 2 NMe 2 , —CH 2 NHEt, —CH 2 NEt 2 , or —CH(NHMe)CH 2 OH.
  • -Q 1 is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, or —NEt 2 .
  • —R SN is independently —H or saturated aliphatic C 1-4 alkyl.
  • —R SN is independently —H, -Me, or -Et.
  • —R SN is independently —H.
  • —R J is independently —NH 2 , —NHMe, —NMe 2 , —NHEt, —NEt 2 , —NH(nPr), —N(nPr) 2 , —NH(iPr), —N(iPr) 2 , piperidino, piperazino, or morpholino.
  • —R J is independently —NH 2 , —NHMe, —NMe 2 , or morpholino.
  • —R J is independently —NH 2 , —NHMe, or —NMe 2 .
  • the APSAC compound has a molecular weight of from 317 to 1200.
  • the bottom of range is 325, 350, 375, 400, 425, 450, 500.
  • the top of range is 1100, 1000, 900, 800, 700, or 600.
  • the range is from 350 to 700.
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from a compound of the following formula and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds are selected from compounds of the following formulae and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compounds is selected from a compound of the following formula and pharmaceutically acceptable salts, hydrates, and solvates thereof:
  • the compound may have one or more chiral centres.
  • the chiral centre, or each chiral centre, if more than one is present, is independently in the R-configuration or the S-configuration.
  • One aspect of the present invention pertains to APSAC compounds, as described herein, in substantially purified form and/or in a form substantially free from contaminants.
  • the substantially purified form is at least 50% by weight, e.g., at least 60% by weight, e.g., at least 70% by weight, e.g., at least 80% by weight, e.g., at least 90% by weight, e.g., at least 95% by weight, e.g., at least 97% by weight, e.g., at least 98% by weight, e.g., at least 99% by weight.
  • the substantially purified form refers to the compound in any stereoisomeric or enantiomeric form.
  • the substantially purified form refers to a mixture of stereoisomers, i.e., purified with respect to other compounds.
  • the substantially purified form refers to one stereoisomer, e.g., optically pure stereoisomer.
  • the substantially purified form refers to a mixture of enantiomers.
  • the substantially purified form refers to an equimolar mixture of enantiomers (i.e., a racemic mixture, a racemate).
  • the substantially purified form refers to one enantiomer, e.g., optically pure enantiomer.
  • the contaminants represent no more than 50% by weight, e.g., no more than 40% by weight, e.g., no more than 30% by weight, e.g., no more than 20% by weight, e.g., no more than 10% by weight, e.g., no more than 5% by weight, e.g., no more than 3% by weight, e.g., no more than 2% by weight, e.g., no more than 1% by weight.
  • the contaminants refer to other compounds, that is, other than stereoisomers or enantiomers. In one embodiment, the contaminants refer to other compounds and other stereoisomers. In one embodiment, the contaminants refer to other compounds and the other enantiomer.
  • the substantially purified form is at least 60% optically pure (i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer), e.g., at least 70% optically pure, e.g., at least 80% optically pure, e.g., at least 90% optically pure, e.g., at least 95% optically pure, e.g., at least 97% optically pure, e.g., at least 98% optically pure, e.g., at least 99% optically pure.
  • 60% optically pure i.e., 60% of the compound, on a molar basis, is the desired stereoisomer or enantiomer, and 40% is the undesired stereoisomer or enantiomer
  • at least 70% optically pure e.g., at least 80% optically pure, e.g., at least 90% optically pure, e
  • Certain compounds may exist in one or more particular geometric, optical, enantiomeric, diasteriomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and ( ⁇ ) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; ⁇ - and ⁇ -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-, and halfchair-forms; and combinations thereof, hereinafter collectively referred to as “isomers” (or “isomeric forms”).
  • isomers are structural (or constitutional) isomers (i.e., isomers which differ in the connections between atoms rather than merely by the position of atoms in space).
  • a reference to a methoxy group, —OCH 3 is not to be construed as a reference to its structural isomer, a hydroxymethyl group, —CH 2 OH.
  • a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl.
  • a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g., C 1-7 alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).
  • C 1-7 alkyl includes n-propyl and iso-propyl
  • butyl includes n-, iso-, sec-, and tert-butyl
  • methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl
  • keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.
  • H may be in any isotopic form, including 1 H, 2 H (D), and 3 H (T); C may be in any isotopic form, including 12 C, 13 C, and 14 C; O may be in any isotopic form, including 16 O and 18 O; and the like.
  • a reference to a particular compound includes all such isomeric forms, including mixtures (e.g., racemic mixtures) thereof.
  • Methods for the preparation (e.g., asymmetric synthesis) and separation (e.g., fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.
  • a corresponding salt of the compound for example, a pharmaceutically-acceptable salt.
  • pharmaceutically acceptable salts are discussed in Berge et al., 1977, “Pharmaceutically Acceptable Salts,” J. Pharm. Sci ., Vol. 66, pp. 1-19.
  • a salt may be formed with a suitable cation.
  • suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + , alkaline earth cations such as Ca 2+ and Mg 2+ , and other cations such as Al +3 .
  • Suitable organic cations include, but are not limited to, ammonium ion (i.e., NH 4 + ) and substituted ammonium ions (e.g., NH 3 R + , NH 2 R 2 + , NHR 3 + , NR 4 + ).
  • suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine.
  • An example of a common quaternary ammonium ion is N(CH 3 ) 4 + .
  • a salt may be formed with a suitable anion.
  • suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.
  • Suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric.
  • a reference to a particular compound also includes salt forms thereof.
  • solvate is used herein in the conventional sense to refer to a complex of solute (e.g., compound, salt of compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.
  • a reference to a particular compound also includes solvate and hydrate forms thereof.
  • an appropriate biphenyl compound is prepared from a boronic acid and bromobenzene via a Suzuki coupling, for example, as described by O'Brien et al., 2000.
  • the biphenyl is sulfonylated using chlorosulfonic acid to give the corresponding sulfonic acid.
  • the acid is then reacted with thionyl chloride to give the corresponding aryl sulfonyl chloride.
  • the sulfonyl chloride is coupled with an amine to give the corresponding sulfonamide.
  • the sulfonamide can be formed first, from a suitable bromobenzene sulfonyl chloride and amine, and the biphenyl compound then prepared by a similar Suzuki methodology.
  • a suitable bromobenzene sulfonyl chloride and amine and the biphenyl compound then prepared by a similar Suzuki methodology.
  • An example of such a method is shown in the following scheme.
  • the cyclohexanol can be replaced by a cyclohexane methyl alcohol, by coupling of the sulfonyl chloride with a carboxylic ester and subsequent reduction.
  • the biphenyl sulfonyl chloride can be reacted with 4-amino-cyclohexane-carboxylic acid methyl ester in a solvent, such as DCM, in the presence of a suitable base, such as pyridine, and then reduced, for example, with lithium aluminium hydride in a solvent, such as THF, to give the desired alcohol.
  • a solvent such as DCM
  • a suitable base such as pyridine
  • the cyclohexane moiety can be replaced by other carbocycles to give a range of target compounds.
  • each of the four isomers of 3-amino-cyclopentane carboxylic acid and each of the four isomers of 3-amino-cyclopentane acetic acid are known and available and can be coupled with the required sulfonyl chloride and subsequently reduced, for example, with lithium aluminium hydride, to give the desired alcohol. Examples of such methods are shown in the following schemes.
  • the alcohol can be replaced by an amide by direct reaction of the sulfonyl chloride with the required aminocarboxylic acid, subsequent chlorination of the acid, and coupling with the required amine.
  • a biphenylsulfonyl chloride can be coupled with 4-aminocyclohexane carboxylic acid in a solvent, such as DCM, in the presence of a base, such as pyridine, the acid chlorinated by reflux in thionyl chloride, in a solvent such as DCM, and then coupled with methylamine in a solvent such as THF.
  • the amide is reduced to the corresponding amine by reaction with a suitable reducing agent.
  • a suitable reducing agent for example, the amide can be reduced by lithium aluminium hydride in a solvent such as THF.
  • An example of such a method is shown in the following scheme.
  • the amino group can be introduced by direct reaction of a suitable amine with a sulfonyl chloride.
  • a sulfonyl chloride for example a biphenyl sulfonyl chloride can be coupled with 1,4-diaminocyclohexane in a solvent, such as DCM, in the presence of a suitable base, such as pyridine.
  • a solvent such as DCM
  • a suitable base such as pyridine
  • amino substitutions may be made by nucleophilic attack of a suitable amine on a cyclohexanone.
  • the cyclohexanone can be prepared from the cyclohexanol derivative by use of Jones' oxidation (chromium trioxide/sulfuric acid), subsequent reaction with methylamine, and reduction in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride in a solvent, such as methanol or THF.
  • Jones' oxidation chromium trioxide/sulfuric acid
  • methylamine methylamine
  • reduction in the presence of sodium cyanoborohydride or sodium triacetoxyborohydride in a solvent, such as methanol or THF such as methanol or THF.
  • amine can be reacted with an acid chloride or anhydride, to give an amide, which may then be further reduced to give the secondary amine.
  • the amine can be acylated with trifluoroacetic anhydride in the presence of triethylamine and then reduced with borane in a solvent such as THF. The mixture of products may then be separated by preparative HPLC to give the cis- and trans-isomers.
  • An example of such a method is shown in the following scheme.
  • the cyclohexanone intermediate can be used to prepare cis- or trans-isomers where the required starting material is unavailable.
  • the cyclohexanone derivative can be prepared from trans-4-aminocyclohexanol and reduced with LS-Selectride (lithium trisiamylborohydride) in THF to give the cis-isomer as the final product.
  • LS-Selectride lithium trisiamylborohydride
  • the cyclohexanone intermediate can be reduced with a Grignard reagent to give the tertiary alcohol.
  • the cyclohexanone can be reacted with methyl magnesium bromide and the racemic mixture separated by preparative HPLC to give the cis- and trans-isomers.
  • An example of such a method is shown in the following scheme.
  • trans-4-aminocyclohexanol can be amino-protected with a suitable protecting group, oxidised to the cyclohexanone, reacted with a suitable Grignard, and then separated, prior to deprotection and coupling.
  • the amine can be BOC protected, using di-tert-butyl dicarbonate, the alcohol oxidised using pyridinium chlorochromate, the cyclohexanone reacted with methylmagnesium chloride and the BOC protecting group removed with a reagent such as trifluoroacetic acid or ethanolic HCl, following separation of the isomers by column chromatography.
  • a reagent such as trifluoroacetic acid or ethanolic HCl
  • the biphenyl sulfonamide group can be replaced by a heteroaryl-phenyl sulfonamide motif by preparation of any of the above derivatives as a bromophenyl sulfonamide derivative, preparation of the boronic acid or boronate, and subsequent Suzuki coupling with a substituted pyridyl bromide, at a suitable stage of the reaction pathway.
  • bromobenzene sulfonamide compounds can be prepared from the cyclohexanol, cyclohexane carboxylic acid, and cyclopentane carboxylic acid compounds described in the above schemes. These can then be reacted with bis(pinacolato)diboron to give the required borane, which can then be coupled with an appropriate heterocyclic bromide using Suzuki coupling. Examples of such methods are shown in the following schemes.
  • all four 2-aminocyclopentane carboxylate isomers can be prepared by reductive amination of ethyl 2-oxocyclopentanecarboxylate and used to prepare the respective sulfonamide-cyclopentane methyl alcohol compound.
  • ethyl 2-oxocyclopentanecarboxylate can be reacted with ammonium acetate and then reduced with sodium triacetoxyborohydride to give the racemic mixture of 2-aminocarboxylates, which may be separated by HPLC, or further coupled with a biphenyl sulfonyl chloride, reduced with lithium aluminium hydride and then separated.
  • An example is shown in the following scheme.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising an APSAC compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
  • compositions e.g., a pharmaceutical composition
  • a composition comprising admixing an APSAC compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.
  • APSAC compounds described herein are believed to be anti-inflammatory agents, which may act by blockade or modification of pro-inflammatory signalling pathways (for example those mediated by TNF ⁇ signalling and NF ⁇ B or AP-1 activation) and thus may prevent inflammation or suppress autoimmune responses or offer protection against joint destruction and other effects of chronic inflammatory disease.
  • pro-inflammatory signalling pathways for example those mediated by TNF ⁇ signalling and NF ⁇ B or AP-1 activation
  • APSAC compounds described herein are also believed to be anti-resorptive agents, which may act by blockade or modification of pathways that lead to excessive osteoclast activity (for example those mediated by RANKL, TNF ⁇ , and IL-1 signalling and NF ⁇ B activation) and thereby protect against the bone loss seen in osteoporosis and many chronic inflammatory conditions.
  • APSAC compounds described herein are believed to be useful in the treatment of inflammation and/or joint destruction and/or bone loss.
  • the APSAC compounds described herein are believed to be useful in the treatment of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system.
  • the APSAC compounds described herein are believed to be useful in the treatment of, inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • inflammatory and autoimmune disorders for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like.
  • the APSAC compounds described herein are believed to be useful in the treatment of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activation in rheumatoid arthritis; osteoporosis; cancer-associated bone disease; Paget's disease; and the like.
  • the APSAC compounds described herein are believed to be useful in the treatment of haematological malignancies, e.g., multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma), e.g., haematological malignancies, multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma) associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation.
  • haematological malignancies e.g., multiple myeloma, leukaemia, or lymphoma
  • haematological malignancies e.g., multiple myeloma, leukaemia, or lymphoma
  • haematological malignancies e.g., multiple myeloma, leukaemia, or lymphoma
  • haematological malignancies e.g., multiple
  • the APSAC compounds described herein are believed to be useful in the treatment of solid tumour cancers, e.g., cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, or melanoma, e.g., solid tumour cancers, cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, and melanoma associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation.
  • solid tumour cancers e.g., cancer of the bladder, breast cancer (female and/or male)
  • colon cancer e.g., kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, and melanoma associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation.
  • the APSAC compounds described herein are believed to be useful in the treatment of a haematological malignancy, e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia, e.g., a haematological malignancy, T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a haematological malignancy e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy
  • the APSAC compounds described herein are believed to be useful in the treatment of a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer or basal cell ameloblastoma, e.g., a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer, or basal cell ameloblastoma associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a solid tumour cancer e.g., renal cell carcinoma, breast cancer (female and/or male)
  • gastric cancer e.g., renal cell carcinoma, breast cancer (female and/or male)
  • gastric cancer e.g., prostate cancer, colon cancer
  • One aspect of the invention pertains to a method of inhibiting an inflammatory response, in vitro or in vivo, comprising contacting an immune system component with an effective amount of an APSAC compound, as described herein.
  • One aspect of the invention pertains to a method of inhibiting cellular and/or molecular pathways leading to joint destruction, in vitro or in vivo, comprising contacting cells associated with an immune response with a therapeutically-effective amount of an APSAC compound, as described herein.
  • One aspect of the invention pertains to a method of inhibiting osteoclast survival, formation, and/or activity, in vitro or in vivo, comprising contacting an osteoclast with an effective amount of an APSAC compound, as described herein.
  • One aspect of the invention pertains to a method of inhibiting bone resorption, in vitro or in vivo, comprising contacting cells in the bone microenvironment with a therapeutically-effective amount of an APSAC compound, as described herein.
  • immune system component relates to, but is not restricted to, cells such as macrophages, T-cells, B-cells, NK-cells, monocytes, neutrophils, dendritic cells, lymphocytes, leukocytes, granulocytes, antigen-presenting cells, and other cells of the haematopoietic lineage including osteoclasts.
  • cells in the bone microenvironment pertains to cells such as osteoblasts, osteoclasts, osteocytes, and bone marrow stromal cells, which are located in close proximity to bone (e.g., within one hundred micrometers of the bone surface).
  • Another aspect of the present invention pertains to an APSAC compound, as described herein, for use in a method of treatment of the human or animal body by therapy.
  • Another aspect of the present invention pertains to use of an APSAC compound, as described herein, in the manufacture of a medicament for use in treatment.
  • the medicament comprises the APSAC compound.
  • Another aspect of the present invention pertains to a method of treatment comprising administering to a patient in need of treatment a therapeutically effective amount of an APSAC compound, as described herein, preferably in the form of a pharmaceutical composition.
  • the treatment is treatment of an inflammatory disorder or an autoimmune disorder.
  • the treatment is treatment of a disorder associated with inflammation and/or activation of the immune system.
  • the treatment is treatment of a disorder mediated by excessive and/or inappropriate and/or prolonged activation of the immune system.
  • the treatment is treatment of inflammation.
  • the treatment is treatment of a disorder associated with inflammation or activation of the immune system.
  • the treatment is treatment of rheumatoid arthritis.
  • the treatment is treatment of psoriasis.
  • the treatment is treatment of psoriatic arthritis.
  • the treatment is treatment of chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the treatment is treatment of atherosclerosis.
  • the treatment is treatment of ankylosing spondylitis.
  • the treatment is treatment of inflammatory bowel disease.
  • the treatment is prevention of an immune response leading to organ or graft rejection following transplant.
  • the treatment is treatment of a tumour which over expresses TNF ⁇ , IL-1, RANKL, or NF ⁇ B, or in which inhibition of TNF ⁇ , IL-1, RANKL, or NF ⁇ B facilitates or improves the action of cytotoxic tumouricidal agents.
  • the treatment is treatment of a haematological malignancy, e.g., multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma), e.g., a haematological malignancy, multiple myeloma, leukaemia, or lymphoma (e.g., non-Hodgkin Lymphoma) associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a haematological malignancy e.g., multiple myeloma, leukaemia, or lymphoma
  • a haematological malignancy e.g., multiple myeloma, leukaemia, or lymphoma
  • NF ⁇ B e.g., non-Hodgkin Lymphoma
  • inflammation
  • the treatment is treatment of a solid tumour cancer, e.g., cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, or melanoma, e.g., a solid tumour cancer, cancer of the bladder, breast cancer (female and/or male), colon cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, and melanoma associated with activation of NF ⁇ B, with aberrant NF ⁇ B signalling, or with inflammation, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a solid tumour cancer e.g., cancer of the bladder, breast cancer (female and/or male)
  • colon cancer e.g., cancer of the bladder, breast cancer (female and/or male
  • colon cancer e.g., a solid tumour cancer, cancer of the bladder, breast cancer
  • the treatment is treatment of a haematological malignancy, e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia, e.g., a haematological malignancy, T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a haematological malignancy e.g., T-cell lymphoblastic lymphoma, mantle cell lymphoma, or acute lymphoblastic leukemia associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • the treatment is treatment of a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer, or basal cell ameloblastoma, e.g., a solid tumour cancer, e.g., renal cell carcinoma, breast cancer (female and/or male), gastric cancer, prostate cancer, colon cancer, or basal cell ameloblastoma associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • a solid tumour cancer e.g., renal cell carcinoma, breast cancer (female and/or male)
  • gastric cancer e.g., prostate cancer, colon cancer
  • basal cell ameloblastoma associated with inactivation or impairment of caspase induction or with aberrant caspase signalling, e.g., alone, or in combination with, and
  • the treatment is part of treatment by combination therapy, e.g., in combination with, and to augment the efficacy of, radiotherapy or chemotherapy.
  • the treatment is treatment of a disease or disorder selected from: diseases having an inflammatory or autoimmune component, including asthma, atherosclerosis, allergic diseases, such as atopy, allergic rhinitis, atopic dermatitis, anaphylaxis, allergic bronchopulmonary aspergillosis, and hypersensitivity pneumonitis (pigeon breeders disease, farmer's lung disease, humidifier lung disease, malt workers' lung disease); allergies, including flea allergy dermatitis in mammals such as domestic animals, e.g., dogs and cats, contact allergens including mosquito bites or other insect sting allergies, poison ivy, poison oak, poison sumac, or other skin allergens; autoimmune disorders, including, but not limited to, type I diabetes and associated complications, multiple sclerosis, arthritis, systemic lupus erythematosus, autoimmune (Hasimoto's) thyroiditis, autoimmune liver diseases such as hepatitis and primary biliary cirrhosis, hyperthyroid
  • Pathol ., Vol. 178, p. 201 skin diseases such as lichen planus, delayed type hypersensitivity, chronic pulmonary inflammation, e.g., pulmonary alveolitis and pulmonary granuloma, gingival inflammation or other periodontal disease, and osseous inflammation associated with lesions of endodontic origin (Volejnikova et al., 1997 , Am. J. Pathol ., Vol. 150, p. 1711), hypersensitivity lung diseases such as hypersensitivity pneumonitis (Sugiyama et al., 1995 , Eur. Respir. J ., Vol. 8, p. 1084), and inflammation related to histamine release from basophils (Dvorak et al., 1996 , J.
  • the treatment is treatment of a disorder mediated by osteoclasts.
  • the treatment is treatment of a disorder characterised by excessive bone resorption.
  • the treatment is treatment of bone loss.
  • the treatment is treatment of bone loss associated with inflammation.
  • the treatment is treatment of bone loss not associated with inflammation.
  • the treatment is treatment of bone loss associated with excessive osteoclast activation.
  • the treatment is treatment of joint destruction.
  • the treatment is treatment of joint destruction associated with inflammation.
  • the treatment is treatment of joint destruction associated with excessive osteoclast activation.
  • the treatment is treatment of bone loss associated with rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease of bone.
  • the treatment is treatment of rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease of bone.
  • the treatment is treatment of neoplasia of bones, whether as a primary tumour or as metastases, including but not limited to, osteosarcoma and osteoma (Zheng et al., 1998 , J. Cell Biochem ., Vol. 70, p. 121) and cancer-associated bone disease (e.g., hypercalcemia of malignancy, bone metastases, osteolytic bone metastases, multiple myeloma, breast carcinoma).
  • cancer-associated bone disease e.g., hypercalcemia of malignancy, bone metastases, osteolytic bone metastases, multiple myeloma, breast carcinoma.
  • the treatment is treatment of hypercalcemia caused by conditions associated with increased bone resorption, including, but not limited to: vitamin D intoxication, primary or tertiary hyperparathyroidism, immobilisation, and sarcoidosis.
  • the treatment is treatment of aseptic loosening of prosthetic implants (e.g., artificial joints, e.g., knees, hips, etc., can loosen due to osteoclast activity driven by local inflammation) (see, e.g., Childs, L. M., et al., 2001 , Journal of Bone and Mineral Research , Vol. 16, No. 2, pp. 338-347).
  • prosthetic implants e.g., artificial joints, e.g., knees, hips, etc.
  • the treatment is treatment of osteopetrosis, osteoarthritis, or ectopic bone formation.
  • treatment pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, alleviatiation of symptoms of the condition, amelioration of the condition, and cure of the condition.
  • Treatment as a prophylactic measure i.e., prophylaxis
  • use with patients who have not yet developed the condition, but who are at risk of developing the condition is encompassed by the term “treatment.”
  • treatment For example, use with perimenopausal women who may not yet have osteoporosis, but who are at risk of osteoporosis, is encompassed by the term “treatment.”
  • terapéuticaally-effective amount pertains to that amount of a compound, or a material, composition or dosage form comprising a compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.
  • treatment includes combination treatments and therapies, in which two or more treatments or therapies are combined, for example, sequentially or simultaneously.
  • treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g., drugs, antibodies (e.g., as in immunotherapy), prodrugs (e.g., as in photodynamic therapy, GDEPT, ADEPT, etc.); surgery; radiation therapy; and gene therapy.
  • APSAC compounds described herein may also be used as cell culture additives to inhibit immune cell function, for example, to inhibit the survival, formation, and/or activity of macrophages, T-cells, or other cells involved in the immune response.
  • APSAC compounds as described herein, may also be used as cell culture additives, for example, to inhibit osteoclasts, for example, to inhibit the survival, formation, and/or activity of osteoclasts.
  • APSAC compounds described herein may also be used as part of an in vitro assay, for example, in order to determine whether a candidate host is likely to benefit from treatment with the compound in question.
  • APSAC compounds described herein may also be used as a standard, for example, in an assay, in order to identify other active compounds, other osteoclast inhibitors, etc.
  • kits comprising (a) an APSAC compound as described herein, or a composition comprising an APSAC compound as described herein, e.g., preferably provided in a suitable container and/or with suitable packaging; and (b) instructions for use, e.g., written instructions on how to administer the compound or composition.
  • the written instructions may also include a list of indications for which the APSAC compound is a suitable treatment.
  • the APSAC compound or pharmaceutical composition comprising the APSAC compound may be administered to a subject by any convenient route of administration, whether systemically/peripherally or topically (i.e., at the site of desired action).
  • Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eyedrops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular
  • the subject/patient may be a chordate, a vertebrate, a mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g
  • the subject/patient may be any of its forms of development, for example, a fetus.
  • the subject/patient is a human.
  • the APSAC compound While it is possible for the APSAC compound to be administered alone, it is preferable to present it as a pharmaceutical formulation (e.g., composition, preparation, medicament) comprising at least one APSAC compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.
  • the formulation may further comprise other active agents, for example, other therapeutic or prophylactic agents.
  • the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one APSAC compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the compound.
  • pharmaceutically acceptable pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
  • Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th edition, 2005.
  • the formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.
  • carriers e.g., liquid carriers, finely divided solid carrier, etc.
  • the formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.
  • Formulations may suitably be in the form of liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, mouthwashes, drops, tablets (including, e.g., coated tablets), granules, powders, losenges, pastilles, capsules (including, e.g., hard and soft gelatin capsules), cachets, pills, ampoules, boluses, suppositories, pessaries, tinctures, gels, pastes, ointments, creams, lotions, oils, foams, sprays, mists, or aerosols.
  • solutions e.g., aqueous, non-aqueous
  • suspensions e.g., aqueous, non-aqueous
  • Formulations may suitably be provided as a patch, adhesive plaster, bandage, dressing, or the like which is impregnated with one or more compounds and optionally one or more other pharmaceutically acceptable ingredients, including, for example, penetration, permeation, and absorption enhancers. Formulations may also suitably be provided in the form of a depot or reservoir.
  • the compound may be dissolved in, suspended in, or admixed with one or more other pharmaceutically acceptable ingredients.
  • the compound may be presented in a liposome or other microparticulate which is designed to target the compound, for example, to blood components or one or more organs.
  • Formulations suitable for oral administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), elixirs, syrups, electuaries, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses.
  • Formulations suitable for buccal administration include mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • Losenges typically comprise the compound in a flavored basis, usually sucrose and acacia or tragacanth.
  • Pastilles typically comprise the compound in an inert matrix, such as gelatin and glycerin, or sucrose and acacia.
  • Mouthwashes typically comprise the compound in a suitable liquid carrier.
  • Formulations suitable for sublingual administration include tablets, losenges, pastilles, capsules, and pills.
  • Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), mouthwashes, losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • solutions e.g., aqueous, non-aqueous
  • suspensions e.g., aqueous, non-aqueous
  • emulsions e.g., oil-in-water, water-in-oil
  • mouthwashes e.g., losenges, pastilles, as well as patches, adhesive plasters, depots, and reservoirs.
  • Formulations suitable for non-oral transmucosal administration include liquids, solutions (e.g., aqueous, non-aqueous), suspensions (e.g., aqueous, non-aqueous), emulsions (e.g., oil-in-water, water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
  • solutions e.g., aqueous, non-aqueous
  • suspensions e.g., aqueous, non-aqueous
  • emulsions e.g., oil-in-water, water-in-oil
  • suppositories e.g., pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, adhesive plasters, depots, and reservoirs.
  • Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, dressings, depots, and reservoirs.
  • Tablets may be made by conventional means, e.g., compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the compound in a free-flowing form such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethyl cellulose); fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc, silica); disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose); surface-active or dispersing or wetting agents (e.g., sodium lauryl sulfate); preservatives (e.g., methyl p-hydroxybenzoate, propyl
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the compound therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile.
  • Tablets may optionally be provided with a coating, for example, to affect release, for example an enteric coating, to provide release in parts of the gut other than the stomach.
  • Ointments are typically prepared from the compound and a paraffinic or a water-miscible ointment base.
  • Creams are typically prepared from the compound and an oil-in-water cream base.
  • the aqueous phase of the cream base may include, for example, at least about 30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof.
  • the topical formulations may desirably include a compound which enhances absorption or penetration of the compound through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.
  • Emulsions are typically prepared from the compound and an oily phase, which may optionally comprise merely an emulsifier (otherwise known as an emulgent), or it may comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil.
  • an emulsifier also known as an emulgent
  • a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat.
  • the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax
  • the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.
  • Suitable emulgents and emulsion stabilisers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate.
  • suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the compound in most oils likely to be used in pharmaceutical emulsion formulations may be very low.
  • the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers.
  • Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters known as Crodamol CAP may be used, the last three being preferred esters. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
  • Formulations suitable for intranasal administration, where the carrier is a liquid include, for example, nasal spray, nasal drops, or by aerosol administration by nebuliser, include aqueous or oily solutions of the compound.
  • Formulations suitable for intranasal administration, where the carrier is a solid include, for example, those presented as a coarse powder having a particle size, for example, in the range of about 20 to about 500 microns which is administered in the manner in which snuff is taken, i.e., by rapid inhalation through the nasal passage from a container of the powder held close up to the nose.
  • Formulations suitable for pulmonary administration include those presented as an aerosol spray from a pressurised pack, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
  • a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichoro-tetrafluoroethane, carbon dioxide, or other suitable gases.
  • Formulations suitable for ocular administration include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.
  • Formulations suitable for rectal administration may be presented as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
  • a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, for example, cocoa butter or a salicylate; or as a solution or suspension for treatment by enema.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the compound, such carriers as are known in the art to be appropriate.
  • Formulations suitable for parenteral administration include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the compound is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate).
  • sterile liquids e.g., solutions, suspensions
  • Such liquids may additional contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient.
  • excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like.
  • suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection.
  • concentration of the compound in the liquid is from about 1 ng/mL to about 100 ⁇ g/mL, for example from about 10 ng/mL to about 10 ⁇ g/mL, for example from about 10 ng/mL to about 1 ⁇ g/mL.
  • the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • sterile liquid carrier for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.
  • APSAC compounds can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects.
  • the selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular APSAC compound, the route of administration, the time of administration, the rate of excretion of the APSAC compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient.
  • the amount of APSAC compound and route of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.
  • Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.
  • a suitable dose of the APSAC compound is in the range of about 10 ⁇ g to about 250 mg (more typically about 100 ⁇ g to about 25 mg) per kilogram body weight of the subject per day.
  • the compound is a salt, an ester, an amide, a prodrug, or the like
  • the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.
  • Method B ABD598 (1.0 g) was dissolved in a mixture of toluene (15 mL) and ethanol (15 mL). 2,4-Difluorophenylboronic acid (1 g) was added followed by (PPh 3 ) 4 Pd (0.15 g). The mixture was stirred vigorously under N 2 and 2 M Na 2 CO 3 (15 mL) added. The mixture was refluxed with stirring for 3 hours under an atmosphere of N 2 . The organic solvents were removed under vacuum, the residue dissolved in ethyl acetate and washed with water and saturated NaCl solution.
  • 2,4-Difluorophenylboronic acid (15 g, 129 mmol) was added to a solution of bromobenzene (19.8 g, 126 mmol) in DME (500 mL). To this was added a solution of sodium carbonate (55.8 g, 520 mmol) in water (260 mL). The solution was degassed by bubbling argon through the mixture and then stirred under argon. Pd(dppf)Cl 2 (1.5 g, 2.1 mmol) was added and the mixture heated overnight at 90° C. under argon. The mixture was cooled to room temperature and water (150 mL) and ethyl acetate (500 mL) were added.
  • 2,4-Difluorobiphenyl (21.2 g, 111 mmol) was dissolved in chloroform (120 mL) and chlorosulfonic acid (12.5 mL, 188 mmol) was added dropwise. The mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo and the residue taken up into EtOAc (100 mL) and washed with water (3 ⁇ 25 mL). The organics were shaken with brine, whereupon a flocculent solid formed. This was filtered and washed with EtOAc and dried to give 2′,4′-difluorobiphenyl-4-sulfonic acid as an off-white solid (12.1 g).
  • a solution of ABD776a (100 mg, 0.24 mmol) in dry THF (10 mL) was cooled to 0° C. under argon and 1 M LiAlH 4 in THF (1.22 mL, 1.22 mmol) was added by syringe. The mixture was stirred overnight, allowing it to warm to room temperature. The solution was then cooled to 0° C. before saturated NH 4 Cl (5 mL) and EtOAc (20 mL) were added. The mixture was filtered through Celite and the layers separated.
  • Jones' reagent was prepared by dissolving CrO 3 (1.33 g, 13.3 mmol) in concentrated H 2 SO 4 (1.15 mL) and diluting the mixture up to 5 mL with water.
  • a solution of ABD598 (390 mg, 1.17 mmol) in acetone (15 mL) was stirred at room temperature and Jones' reagent was added dropwise until an orange colour persisted.
  • TLC indicated complete consumption of the starting material and the formation of a new, less polar, compound.
  • the mixture was filtered through Celite, the solvent was evaporated and the residue taken up in EtOAc (50 mL). The solution was washed with water (2 ⁇ 10 mL) and 10% aqueous Na 2 S 2 O 3 (2 ⁇ 10 mL) and dried over MgSO 4 . Evaporation of the solvent gave the title compound as a white solid (390 mg).
  • a solution of ABD777b (205 mg, 0.62 mmol) in dry THF (5 mL) was cooled to 0° C. under argon.
  • 1 M LS-Selectride in THF (1.32 mL, 1.32 mmol) was added by syringe and the solution was stirred for 1 hour.
  • Water (1 mL) was added and the mixture was stirred for 10 minutes before being diluted with EtOAc (20 mL) and 1 M HCl (4 mL). The layers were separated and the organic phase was washed with water (5 mL) and brine (5 mL) and dried over MgSO 4 .
  • Method C ABD777a (160 mg, 0.48 mmol), 2,4-difluorophenylboronic acid (113 mg, 0.72 mmol) and 1 M Na 2 CO 3 solution (1 mL, 1 mmol) were stirred in DME and the flask was flushed with argon. Pd(dppf)Cl 2 (17 mg, 0.02 mmol) was added and the flask was placed into an oil bath that had been pre-heated to 90° C. and stirred for 1.5 hours. The mixture was cooled, poured into EtOAc (30 mL) and washed with water (5 mL) and brine (5 mL).
  • a solution of ABD781a (123 mg, 0.30 mmol) in dry THF (3 mL) was cooled under argon to 0° C. and 1 M LiAlH 4 in THF (1.5 mL, 1.5 mmol) was added by syringe. The mixture was stirred for 2 hours, whilst warming to room temperature. Ice and water were then added and the mixture was adjusted to pH 2 with 2 M HCl and extracted with EtOAc (4 ⁇ 10 mL). The combined extracts were washed with brine (10 mL), dried over MgSO 4 and evaporated.
  • a solution of ABD776a (100 mg, 0.24 mmol) in dry THF (10 mL) was cooled under argon to 0° C. 3 M Methylmagnesium bromide solution in Et 2 O (25 ⁇ L, 0.75 mmol) was added by syringe and the mixture was stirred for 2 hours, allowing it to warm to room temperature. The solution was cooled to 0° C. and saturated NH 4 Cl solution (2 mL) was added, followed by water to dissolve the solids. The mixture was extracted with EtOAc (3 ⁇ 10 mL) and the combined extracts were washed with brine (5 mL) and water (5 mL) and dried over MgSO 4 .
  • a solution of ABD781a 300 mg, 0.73 mmol in dry THF (10 mL) was cooled under argon to 0° C. and 3 M methylmagnesium bromide in Et 2 O (0.97 mL, 2.93 mmol) was added by syringe. The ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour. Saturated NH 4 Cl (2 mL) was then added and the mixture was stirred a further 10 minutes before being diluted with water (10 mL) and diethyl ether (20 mL). The layers were separated and the aqueous phase was extracted with diethyl ether (2 ⁇ 10 mL).
  • a solution of ABD786 (200 mg, 0.55 mmol) in dry THF (5 mL) was stirred at room temperature and 2 M dimethylamine in THF (0.55 mL, 1.10 mmol) was added by syringe.
  • the solution was cooled to 0° C. under argon and sodium triacetoxyborohydride (150 mg, 0.71 mmol) was added in one portion.
  • the reaction mixture was stirred at 0° C. for 1 hour and then at room temperature overnight.
  • TLC indicated incomplete reaction so further 2 M dimethylamine in THF (0.5 mL, 1 mmol) and sodium triacetoxyborohydride (100 mg, 0.47 mmol) were added. After a further 24 hours, 2 M NaOH (3 mL) was added.
  • Ethyl cis-2-aminocyclopentanecarboxylate hydrochloride (390 mg, 2.0 mmol) and 2′,4′-difluorobiphenylsulfonyl chloride (480 mg, 1.67 mmol) were stirred in DCM (5 mL) and pyridine (400 ⁇ L) was added. The mixture was stirred at room temperature overnight, after which TLC indicated both starting materials were still present. DMAP (10 mg) and additional pyridine (1 mL) were added and stirring was continued for a further 24 hours, when TLC indicated no starting materials remained and a new compound had formed. The reaction mixture was diluted with DCM (10 mL) and water (5 mL) and conc.
  • N-(cis-4-(2,4-Dimethoxybenzylamino)cyclohexyl)-2′,4′-difluorobiphenyl-4-sulfonamide (see ABD787a) (52 mg, 0.10 mmol) was stirred in acetonitrile (3 mL) and water (1 mL) and ceric ammonium nitrate (144 mg, 0.26 mmol) was added. The mixture was stirred at 50° C. overnight and then diluted with EtOAc (15 mL) and washed with water (2 ⁇ 5 mL). The washings were extracted with EtOAc (5 mL) and the combined organics were dried over MgSO 4 .
  • a solution of ABD813a (105 mg, 0.27 mmol) in dry THF (5 mL) was cooled under argon to 0° C. and LiAlH 4 (1 M in THF, 1.33 mL, 1.33 mmol) was added by syringe. After 5 minutes the ice bath was removed and the solution was stirred at room temperature for 2 hours. After cooling back to 0° C., the reaction was quenched by adding Na 2 SO 4 10.H 2 O ( ⁇ 500 mg) cautiously. Once bubbling had stopped the mixture was diluted with EtOAc (10 mL) and stirred for 1 hour at room temperature before being filtered, rinsing the solids well with EtOAc.
  • a solution of ABD786 (250 mg, 0.68 mmol) in dry THF (5 mL) was stirred under argon and methylamine (2 M in THF, 1.35 mL) was added by syringe. The solution was stirred for 1 hour and then STAB (360 mg, 1.7 mmol) was added in one portion. The mixture was stirred at room temperature overnight. TLC indicated starting material to still be present, and so further methylamine (2 M in THF, 1.35 mL) and STAB (360 mg, 1.7 mmol) and a drop of acetic acid were added and stirring was continued for a further 3 days.
  • a solution of ABD786 (250 mg, 0.68 mmol) in dry THF (5 mL) was stirred under argon and ethylamine (2 M in THF, 1.35 mL) was added by syringe. The solution was stirred for 1 hour and then STAB (360 mg, 1.7 mmol) was added in one portion. The mixture was stirred at room temperature overnight. TLC indicated starting material to still be present, and so further ethylamine (2 M in THF, 1.35 mL) and STAB (360 mg, 1.7 mmol) and a drop of acetic acid were added and stirring was continued for a further 3 days.
  • ABD786 (450 mg, 1.23 mmol) was stirred in DCM (5 mL) and i PrNH 2 (160 ⁇ L, 110 mg, 1.85 mmol) was added and the solution was stirred overnight at room temperature. It was then diluted with further DCM (5 mL) and STAB (1.30 g, 6.15 mmol) was added and stirring was continued for 2 hours. 2 M NaOH (aq., 7 mL) and EtOAc (30 mL) were added and the mixture was stirred for a further 30 minutes before the layers were separated.
  • a solution of methylamine (2 M in THF, 5.8 mL, 11.6 mmol) in dry DCM (15 mL) was cooled under argon to 0° C. and the solution of the acid chloride was added by cannula, resulting in the formation of a precipitate.
  • a solution of ABD824a (240 mg, 0.59 mmol) in dry THF (10 mL) was cooled to 0° C. under argon and BH 3 (1 M in THF, 1.8 mL, 1.8 mmol) was added by syringe. The solution was stirred overnight, allowing it to warm to room temperature, after which TLC indicated that starting material was still present, as well as a more polar compound. Further BH 3 (1 M in THF, 1.0 mL, 1.0 mmol) was added and the solution was heated at reflux for 3 hours. After cooling to room temperature, the reaction was quenched with NH 4 Cl (sat. aq., 5 mL) and water was added to dissolve the solids.
  • ABD598 500 mg, 1.5 mmol
  • bis(pinacolato)diboron 420 mg, 1.65 mmol
  • KOAc 294 mg, 3 mmol
  • Pd(dppf)Cl 2 55 mg, 0.08 mmol
  • DMSO dimethyl sulfoxide
  • the reaction mixture was then cooled to room temperature and poured into water (40 mL) and extracted with EtOAc (3 ⁇ 20 mL). The combined organics were washed with water (20 mL) and brine (10 mL), dried (Na 2 SO 4 ) and filtered. Evaporation gave a brown solid (555 mg), containing both the boronic acid and the ester, which was used without further purification.
  • ABD836a (278 mg, 0.92 mmol) was dissolved in DME (4 mL) and 2-bromo-3,5-dichloropyridine (171 mg, 0.76 mmol), Pd(dppf)Cl 2 (23 mg, 5 mol %) and Na 2 CO 3 (2 M soln, 1.15 mL, 2.30 mmol) were added.
  • the mixture was placed in an ultrasonic bath under a stream of argon for 5 minutes. It was then placed in a preheated oil bath (90° C.) for 1.75 hours. After this time, the reaction mixture was cooled to room temperature and poured into water (80 mL) and extracted with EtOAc (3 ⁇ 60 mL).
  • a solution ABD836a (278 mg, 0.92 mmol) in DME (4 mL) was stirred and 2,5-dichloropyrimidine (112 mg, 0.76 mmol), Pd(dppf)Cl 2 (23 mg, 5 mol %) and Na 2 CO 3 (2 M soln, 1.15 mL, 2.30 mmol) were added.
  • the mixture was placed in an ultrasonic bath under a stream of argon for 5 minutes. It was then placed in a preheated oil bath (90° C.) for 1 hour. After this time, the reaction mixture was cooled to room temperature and poured into water (80 mL) and extracted with EtOAc (3 ⁇ 60 mL).
  • a solution of ABD836a (225 mg, 0.78 mmol) in DME (4 mL) was stirred at room temperature and 5-bromopyrimidine (99 mg, 0.63 mmol), Pd(dppf)Cl 2 (23 mg, 0.03 mmol) and Na 2 CO 3 (2 M aq., 0.95 mL) were added.
  • the mixture was placed in an ultrasonic bath under a stream of argon for 5 minutes and then in an oil bath that had been pre-heated to 90° C.
  • the reaction mixture was heated for 1 hour and then cooled to room temperature, diluted with water (20 mL) and extracted with EtOAc (3 ⁇ 10 mL).
  • a solution of ABD787 (410 mg, 1.12 mmol) in dry THF (10 ml) was stirred at room temperature and triethylamine (350 ⁇ L, 250 mg, 2.5 mmol) and TFAA (200 ⁇ L, 300 mg, 1.44 mmol) were added, causing the solution to turn deep red and get warm.
  • the mixture was stirred at room temperature for 3 hours and then poured into water (10 mL) and EtOAc (20 mL) and the layers were separated.
  • the organic phase was washed with water (10 mL) and sat. NaHCO 3 (aq., 10 mL) and dried over MgSO 4 . After evaporation of the solvents, the crude product was purified by column chromatography on SiO 2 (1:1 acetone/hexane) to give the title compound as a waxy orange solid (370 mg, 71%).
  • trans-4-Aminocyclohexanol hydrochloride (13.5 g) was suspended in dry DCM (100 mL) and cooled to 5-10° C. To this, BOC anhydride (24.6 mL, 23.32 g, 106.8 mmol) was added drop-wise over 15 minutes. The reaction mixture was stirred under nitrogen for 15 minutes. Triethylamine (37.2 mL) was added and the mixture was stirred overnight, allowing the temperature to rise to room temperature. The solution was diluted with water (100 mL) and extracted with DCM (2 ⁇ 50 mL), organic layer dried over Na 2 SO 4 . Evaporation of the solvents gave the title compound as a colorless solid (17.1 g, quantitative).
US13/063,956 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use Active 2030-04-18 US8435968B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/063,956 US8435968B2 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9827108P 2008-09-19 2008-09-19
GB0817207.4 2008-09-19
GBGB0817207.4A GB0817207D0 (en) 2008-09-19 2008-09-19 therapeutic apsac compounds and their use
PCT/GB2009/002221 WO2010032009A1 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US13/063,956 US8435968B2 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/002221 A-371-Of-International WO2010032009A1 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/886,799 Continuation US8822507B2 (en) 2008-09-19 2013-05-03 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Publications (2)

Publication Number Publication Date
US20110172189A1 US20110172189A1 (en) 2011-07-14
US8435968B2 true US8435968B2 (en) 2013-05-07

Family

ID=39951895

Family Applications (5)

Application Number Title Priority Date Filing Date
US13/063,956 Active 2030-04-18 US8435968B2 (en) 2008-09-19 2009-09-18 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US13/886,799 Active US8822507B2 (en) 2008-09-19 2013-05-03 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US14/464,973 Active US9050329B1 (en) 2008-09-19 2014-08-21 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US14/720,237 Active US9302984B2 (en) 2008-09-19 2015-05-22 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US15/075,356 Active US9616037B2 (en) 2008-09-19 2016-03-21 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/886,799 Active US8822507B2 (en) 2008-09-19 2013-05-03 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US14/464,973 Active US9050329B1 (en) 2008-09-19 2014-08-21 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US14/720,237 Active US9302984B2 (en) 2008-09-19 2015-05-22 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US15/075,356 Active US9616037B2 (en) 2008-09-19 2016-03-21 Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use

Country Status (14)

Country Link
US (5) US8435968B2 (hr)
EP (1) EP2344449B1 (hr)
JP (1) JP5771524B2 (hr)
CA (1) CA2736971C (hr)
CY (1) CY1116650T1 (hr)
DK (1) DK2344449T3 (hr)
ES (1) ES2544511T3 (hr)
GB (1) GB0817207D0 (hr)
HR (1) HRP20150839T1 (hr)
PL (1) PL2344449T3 (hr)
PT (1) PT2344449E (hr)
SI (1) SI2344449T1 (hr)
SM (1) SMT201500218B (hr)
WO (1) WO2010032009A1 (hr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050329B1 (en) 2008-09-19 2015-06-09 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US9624167B2 (en) 2013-06-26 2017-04-18 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
US8394858B2 (en) * 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
KR20150000900A (ko) 2012-04-10 2015-01-05 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규한 1-치환된 인다졸 유도체
GB201813312D0 (en) * 2018-08-15 2018-09-26 Modern Biosciences Ltd Compounds and their therapeutic use
GB201905520D0 (en) * 2019-04-18 2019-06-05 Modern Biosciences Ltd Compounds and their therapeutic use

Citations (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
US4948809A (en) 1985-10-02 1990-08-14 Boehringer Mannheim Gmbh Sulphonylalkylamines, processes for the preparation thereof and pharmaceutical compositions containing them
WO1996037492A1 (en) 1995-05-25 1996-11-28 The Du Pont Merck Pharmaceutical Company Isoxazoline and isoxazole derivatives as integrin receptor antagonists
WO1997016433A1 (en) 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
EP0877018A1 (de) 1997-05-09 1998-11-11 Hoechst Aktiengesellschaft Sulfonylaminocarbonsäuren
EP0877019A1 (de) 1997-05-09 1998-11-11 Hoechst Aktiengesellschaft Substituierte Diaminocarbonsäuren
WO1998050342A1 (en) 1997-05-08 1998-11-12 Smithkline Beecham Corporation Protease inhibitors
WO1999037621A1 (en) 1998-01-23 1999-07-29 Aventis Pharma Deutschland Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
WO1999042443A1 (en) 1998-02-04 1999-08-26 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
WO1999059992A1 (en) 1998-05-19 1999-11-25 Aventis Pharma Deutschland Gmbh Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
EP0988018A2 (de) 1998-04-07 2000-03-29 Joachim Schmidt Haftmittel für zahnprothesen
WO2001016137A1 (en) 1999-09-01 2001-03-08 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2002060867A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
WO2003037321A1 (en) 2001-10-31 2003-05-08 The University Court Of The University Of Aberdeen Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
US20030144292A1 (en) 2000-03-21 2003-07-31 Natchus Michael George Carbocyclic side chain containing, N-substituted metalloprotease inhibitors
WO2004000020A1 (de) 2002-06-24 2003-12-31 Bayer Cropscience Aktiengesellschaft Fungizide wirkstoffkombinationen
EP1431267A1 (en) 2001-08-09 2004-06-23 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
EP1491190A1 (en) 2002-03-27 2004-12-29 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
WO2005000020A2 (en) 2003-06-23 2005-01-06 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US6849635B2 (en) 2001-05-07 2005-02-01 Smithkline Beecham Corporation Sulfonamides
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005085189A2 (en) 2004-03-08 2005-09-15 Medical Research Council Analogues of congo red and evaluation of their anti-prion activity
US20050227987A1 (en) 2003-10-23 2005-10-13 Nigel Vicker 11beta-hydroxysteroid dehydrogenase inhibitors
WO2005105712A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
WO2006134467A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2007000020A1 (en) 2005-06-29 2007-01-04 Compumedics Limited Sensor assembly with conductive bridge
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007026962A1 (ja) 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited フェニレン誘導体
US20070191370A1 (en) 2005-12-29 2007-08-16 Arokiasamy Devasagayaraj Multicyclic amino acid derivatives and methods of their use
WO2008000020A1 (en) 2006-06-29 2008-01-03 Fermiscan Australia Pty Limited Improved process
US20080119555A1 (en) 2004-06-04 2008-05-22 Stuart Hamilton Ralston Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
US7560597B2 (en) 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
US7572825B2 (en) 2003-05-07 2009-08-11 The University Court Of The University Of Aberdeen Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
WO2010032010A1 (en) 2008-09-19 2010-03-25 Pimco 2664 Limited Aryl-phenyl-sulfonamide-phenylene compounds and their use
US20100286266A1 (en) 2007-03-21 2010-11-11 The University Court Of The University Of Aberdeen Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
US8207168B2 (en) * 2006-07-25 2012-06-26 Cephalon, Inc. Pyridazinone derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129147A0 (en) 1996-10-16 2000-02-17 American Cyanamid Co The preparation and use of ortho-sulfonamide aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
KR101088922B1 (ko) 2002-09-04 2011-12-01 파마코페이아, 엘엘씨. 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
DE10251170A1 (de) 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2005025554A2 (en) 2003-09-09 2005-03-24 Japan Tobacco Inc. Dipeptidyl peptidase iv inhibitor
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
ATE449760T1 (de) * 2004-03-22 2009-12-15 Southern Res Inst Nichtpeptidinhibitoren von matrixmetalloproteinasen
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
CA2584413A1 (en) 2004-10-29 2006-05-04 Astrazeneca Ab Novel sulphonamide derivatives as glucocorticoid receptor modulators for the treatment of inflammatory diseases
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
WO2008005338A1 (en) * 2006-06-29 2008-01-10 Arena Pharmaceuticals, Inc. Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto
WO2010025235A1 (en) 2008-08-29 2010-03-04 Regents Of The University Of Michigan Selective ligands for the dopamine 3 (d3) receptor and methods of using the same
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use

Patent Citations (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB597810A (en) 1943-04-12 1948-02-04 Gen Printing Ink Corp Improvements in or relating to derivatives of diphenyl
DE1046220B (de) 1956-04-21 1958-12-11 Bayer Ag Verfahren zur Herstellung von Monoazofarbstoffen und deren Metallkomplexverbindungen
US4119784A (en) 1977-07-01 1978-10-10 American Cyanamid Company Anionic substituted sulfonamido biphenyls
DE3000519A1 (de) 1979-02-01 1980-08-14 Byk Gulden Lomberg Chem Fab Sulfonamido-alkansaeuren, ihre verwendung und herstellung sowie sie enthaltende arzneimittel
US4948809A (en) 1985-10-02 1990-08-14 Boehringer Mannheim Gmbh Sulphonylalkylamines, processes for the preparation thereof and pharmaceutical compositions containing them
WO1996037492A1 (en) 1995-05-25 1996-11-28 The Du Pont Merck Pharmaceutical Company Isoxazoline and isoxazole derivatives as integrin receptor antagonists
WO1997016433A1 (en) 1995-10-30 1997-05-09 Smithkline Beecham Corporation Protease inhibitors
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
WO1997033887A1 (en) 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
WO1998023608A1 (en) 1996-11-27 1998-06-04 Dupont Pharmaceuticals Company Novel integrin receptor antagonists
WO1998043962A1 (en) 1997-03-28 1998-10-08 Du Pont Pharmaceuticals Company Heterocyclic integrin inhibitor prodrugs
WO1998050342A1 (en) 1997-05-08 1998-11-12 Smithkline Beecham Corporation Protease inhibitors
EP0877018A1 (de) 1997-05-09 1998-11-11 Hoechst Aktiengesellschaft Sulfonylaminocarbonsäuren
EP0877019A1 (de) 1997-05-09 1998-11-11 Hoechst Aktiengesellschaft Substituierte Diaminocarbonsäuren
US6159995A (en) 1997-05-09 2000-12-12 Aventis Pharma Deutschland Gmbh Substituted diaminocarboxylic acids
US6451824B1 (en) 1997-05-09 2002-09-17 Aventis Pharma Deutschland Gmbh Sulfonylaminocarboxylic acids
WO1999037621A1 (en) 1998-01-23 1999-07-29 Aventis Pharma Deutschland Gmbh Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
WO1999042443A1 (en) 1998-02-04 1999-08-26 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
JPH11246527A (ja) 1998-03-02 1999-09-14 Shionogi & Co Ltd Ｍｍｐ−８阻害剤
EP0988018A2 (de) 1998-04-07 2000-03-29 Joachim Schmidt Haftmittel für zahnprothesen
WO1999059992A1 (en) 1998-05-19 1999-11-25 Aventis Pharma Deutschland Gmbh Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
EP0960882A1 (en) 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
WO2001016137A1 (en) 1999-09-01 2001-03-08 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
US20030144292A1 (en) 2000-03-21 2003-07-31 Natchus Michael George Carbocyclic side chain containing, N-substituted metalloprotease inhibitors
WO2001090077A1 (en) 2000-05-19 2001-11-29 Guilford Pharmaceuticals, Inc. Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses
WO2002060867A2 (en) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
WO2002074298A1 (fr) 2001-03-21 2002-09-26 Ono Pharmaceutical Co., Ltd. Inhibiteurs de production d'il-6
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
US6849635B2 (en) 2001-05-07 2005-02-01 Smithkline Beecham Corporation Sulfonamides
EP1431267A1 (en) 2001-08-09 2004-06-23 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient
WO2003037321A1 (en) 2001-10-31 2003-05-08 The University Court Of The University Of Aberdeen Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
US7745424B2 (en) 2001-10-31 2010-06-29 The Univeristy Court of the University of Aberdeen Alkane diol derivatives as therapeutic agents for the treatment of bone conditions
EP1491190A1 (en) 2002-03-27 2004-12-29 Shionogi & Co., Ltd. Decomposition inhibitor for extracellular matrix of cartilage
WO2004000020A1 (de) 2002-06-24 2003-12-31 Bayer Cropscience Aktiengesellschaft Fungizide wirkstoffkombinationen
US7598289B2 (en) 2003-05-07 2009-10-06 The University Court Of The University Of Aberdeen Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
US7572825B2 (en) 2003-05-07 2009-08-11 The University Court Of The University Of Aberdeen Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions
WO2004106290A1 (ja) 2003-05-14 2004-12-09 Kissei Pharmaceutical Co., Ltd. アミノアルコール誘導体、それを含有する医薬組成物およびそれらの用途
WO2005000020A2 (en) 2003-06-23 2005-01-06 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US20050227987A1 (en) 2003-10-23 2005-10-13 Nigel Vicker 11beta-hydroxysteroid dehydrogenase inhibitors
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005085189A2 (en) 2004-03-08 2005-09-15 Medical Research Council Analogues of congo red and evaluation of their anti-prion activity
WO2005105712A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Sulfonamide derivatives
US20080255240A1 (en) 2004-05-05 2008-10-16 Novo Nordisk A/S Sulfonamide Derivatives
US20080119555A1 (en) 2004-06-04 2008-05-22 Stuart Hamilton Ralston Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions
US7964643B2 (en) 2004-06-04 2011-06-21 The University Court Of The University Of Aberdeen Aryl alkyl sulfonamides as therapeutic agents for the treatment of bone conditions
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
WO2006134467A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2007000020A1 (en) 2005-06-29 2007-01-04 Compumedics Limited Sensor assembly with conductive bridge
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
WO2007026962A1 (ja) 2005-08-31 2007-03-08 Daiichi Sankyo Company, Limited フェニレン誘導体
US20070191370A1 (en) 2005-12-29 2007-08-16 Arokiasamy Devasagayaraj Multicyclic amino acid derivatives and methods of their use
WO2008000020A1 (en) 2006-06-29 2008-01-03 Fermiscan Australia Pty Limited Improved process
US8207168B2 (en) * 2006-07-25 2012-06-26 Cephalon, Inc. Pyridazinone derivatives
US7560597B2 (en) 2007-03-08 2009-07-14 The University Court Of The University Of Aberdeen 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents
US20100286266A1 (en) 2007-03-21 2010-11-11 The University Court Of The University Of Aberdeen Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
WO2010032010A1 (en) 2008-09-19 2010-03-25 Pimco 2664 Limited Aryl-phenyl-sulfonamide-phenylene compounds and their use
US20110190302A1 (en) 2008-09-19 2011-08-04 Pimco 2664 Limited Aryl-Phenyl-Sulfonamide-Phenylene Compounds and Their Use
US8207167B2 (en) 2008-09-19 2012-06-26 Pimco 2664 Limited Aryl-phenyl-sulfonamide-phenylene compounds and their use

Non-Patent Citations (82)

* Cited by examiner, † Cited by third party
Title
Annex to UK Search Report for GB 0705400.0-Jul. 9, 2007.
Annex to UK Search Report for GB 0705400.0—Jul. 9, 2007.
Argus et al., 1958, "Distribution studies with sulphur 35-labelled disulfonamides in tumor-bearing and tumor-free mice", Brit. J. Cancer, vol. 12, pp. 636-644.
Armour K.J., et al., 2001, "Inhibition of bone resorption in vitro and prevention of ovariectomy-induced bone loss in vivo by flurbiprofen nitroxybutylester (HCT1026)," Arthritis and Rheumatism, vol. 44, No. 9, pp. 2185-2192.
Augstein, J., et al., 1965, "Some cardiovascular effects of a series of aryloxyalkylamines 1", J. Med. Chem., vol. 8, pp. 356-367.
Baud et al., 1999, "Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain", Genes Dev., vol. 13, pp. 1297-1308.
Baud et al., 2009, "Is NFkappaB a good target for cancer therapy? Hopes and pitfalls", Nat. Rev. Drug Disc., vol. 8, pp. 33-40.
Baud et al., 2009, "Is NFκB a good target for cancer therapy? Hopes and pitfalls", Nat. Rev. Drug Disc., vol. 8, pp. 33-40.
Brennan et al., 1989, "Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis", Lancet, vol. 2, pp. 244-247.
Brennan et al., 1992, "Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints", Eur. J. Immunol., vol. 22, pp. 1907-1912.
Brennan et al., 1996, "Cytokines in autoimmunity", Curr. Opin. Immunol., vol. 8, pp. 872-877.
CHEMCATS record for Enamine Screening Library, Enamine, Kiev, Ukraine, publication date Jan. 17, 2008, CAS Registry No. 950020-41-4 (2 pages).
CHEMCATS record for LaboTest Stock Catalog, LaboTest, Niederschoena, Germany, publication date Jul. 24, 2007, CAS Registry No. 331653-75-9 (2 pages).
CHEMCATS record for Ryan Scientific Screening Library, Ryan Scientific, Inc., Mt. Pleasant, SC, USA, publication date Jan. 25, 2008, CAS Registry No. 302603-86-7 (2 pages).
CHEMCATS record for Scientific Exchange Product List, Scientific Exchange, Inc., Centre Ossipee, NH, USA, publication date Jan. 30, 2008, CAS Registry No. 312756-83-5 (2 pages).
CHEMCATS records for Nanosyn Compound Library, Nanosyn Combinatorial Synthesis Inc., Menlo Park, CA, USA, publication date Apr. 17, 2007, CAS Registry Nos. 313495-94-2, 313521-07-2 (3 pages).
CHEMCATS records for Spectrum Info Catalog, Spectrum Info Ltd., Kiev, Ukraine, publication date Sep. 5, 2007: CAS Registry No. 885269-21-6, 885269-32-9, 885269-42-1, 885269-85-2, 885269-88-5, 885269-91-0 (7 pages).
Corey EJ, Shibata S, Bakshi RK, 1988, "An effcicient and catalytically enantioselective route to (S)-(-)-Phenyloxirane," J. Org. Chem., vol. 53, pp. 2861-2863.
Coxon, F.P., et al., 2000, "Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298," J.Bone Miner.Res., vol. 15, pp. 1467-1476.
Degenhardt, C.R., et al., 1986, "Synthesis of Ethenylidenebis(phosphonic acid) and its Tetraalkyl Esters," J. Org. Chem., vol. 51, pp. 3488-3490.
Eberhard, A., et al., 1965, "Hydrolysis of Phostonates," J. Amer. Chem. Soc., vol. 87, pp. 253-260.
Elliott et al., 1994, "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis", Lancet, vol. 344, pp. 1105-1110.
Feldmann et al., 1994, "TNF alpha as a therapeutic target in rheumatoid arthritis," Circ. Shock, vol. 43, pp. 179-184.
Feldmann et al., 1996, "Rheumatoid arthritis", Cell, vol. 85, pp. 307-310.
Feldmann et al., 2001, "The role of TNF alpha and IL-1 in rheumatoid arthritis," Curr. Dir. Autoimmun., vol. 3, pp. 188-199.
Firestein et al., 1999, "Signal transduction and transcription factors in rheumatic disease", Arthritis Rheum., vol. 42, pp. 609-621.
Firestein, 1996, "Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors?", Arthritis Rheum., vol. 39, pp. 1781-1790.
Firestein, 2005 "Immunologic mechanisms in the pathogenesis of rheumatoid arthritis", J. Clin. Rheumatol., vol. 11. pp. S39-S44.
Gottlieb, 2005, "Psoriasis: Emerging Therapeutic Strategies", Nat. Rev. Drug Disc., vol. 4, pp. 19-34.
Greig et al., 2006, "Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption", J. Med. Chem., vol. 49: pp. 7487-7492.
Ha-Duong, N-T, et al, 2001, "Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily", J. Med. Chem., vol. 44, pp. 3622-3631.
Herczegh, P., et al, 2002, "Osteoadsorptive Bisphosphonate Derivatives of Fluoroquinolone Antibacterials," J. Med. Chem., vol. 45, pp. 2338-2341.
Hughes, D.E., et al., 1997, "Apoptosis in bone physiology and disease," J. Clin. Pathol.: Molecular Pathology, vol. 50, pp. 132-137.
International Preliminary Report on Patentability (IPRP) for PCT/GB2005/002043.
International Preliminary Report on Patentability (IPRP) for PCT/GB2008/000989.
International Preliminary Report on Patentability (IPRP) for PCT/GB2009/002221.
International Preliminary Report on Patentability (IPRP) for PCT/GB2009/002223.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2005/002043.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2008/000989.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2009/002221.
International Search Report (ISR) and Written Opinion of International Searching Authority (WOISA) for PCT/GB2009/002223.
Jimi et al., 2004, "Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo", Nat. Med., vol. 10, pp. 617-624.
Joosten et al., 1996, "Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra," Arthritis Rheum., vol. 39, pp. 797-809.
Klareskog et al., 2006, "A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs", Ann. Rheum. Dis., vol. 65, pp. 1578-1584.
Klareskog et al., 2006, "Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis," Nat. Clin. Pract. Rheumatol., vol. 2, pp. 425-433.
Kong, Y.Y., et al., 1999, "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," Nature, vol. 397, pp. 315-323.
Korzenik et al., 2006, "Evolving knowledge and therpy of inflammatory bowel disease," Nat. Rev. Drug Disc., vol. 5, pp. 197-209.
Li et al., 2008, "A tumor necrosis factor-[alpha]-mediated pathway promoting autosomal dominant polycystic kidney disease", Nature Medicine, vol. 14(8), pp. 863-868.
Liu, 2005, "Molecular mechanism of TNF signaling and beyond," Cell Res., vol. 15(1), pp. 24-27.
Luckman et al.. 1998, "Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages," J. Bone Miner. Res., vol. 13, pp. 1668-1678.
MacPherson, H; et al., 1999, "Expression and functional role of nitric oxide synthase isoforms in human osteoblast-like cells," Bone, vol. 24, pp. 179-185.
Mantovani, 2009, "Inflaming metastasis", Nature, vol. 457, pp. 36-37.
McInnes et al., 2005, "Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis", Curr. Pain Headache Rep., vol. 9, pp. 405-411.
Mohan et al., 1993, "Structure-Activity Relationship Studies with Symmetric Naphthalenesulfonic Acid Derivatives. Synthesis and Influence of Spacer and Naphthalenesulfonic Acid Moiety on Anti-HIV-1 Activity", J. Med. Chem., vol. 36, pp. 1996-2003.
Mount et al., 2005, "Rheumatoid arthritis market", Nat. Rev. Drug Disc., vol. 2, pp. 11-12.
Mundy, G.R., 1996, "Chapter 1: Bone Remodeling", in Bone Remodeling and its disorders (2nd edition), London, (Ed. Martin Dunitz), pp. 1-11.
Nociari et al., 1998, "A Novel one-step, highly sensitive fluorimetric assay to evaluate cell-mediated cytotoxicity", Journal of Immunological Methods, vol. 213, pp. 157-167.
Nyormoi, O., et al., 2003, "An MMP-2/MMP-9 inhibitor, 5a, enhances apoptosis induced by ligands of the TNF receptor superfamily in cancer cells", Cell Death and Differentiation, vol. 10, pp. 558-569.
O'Brien et al., 2000, "Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors". J. Med. Chem. vol. 43: pp. 156-166.
Peyman, A., et al., 2001, "alphavbeta3 antagonists based on a central thiophene scaffold", Bio. & Med. Chem. Letters, Vo. 11, pp. 2011-2015.
Peyman, A., et al., 2001, "αvβ3 antagonists based on a central thiophene scaffold", Bio. & Med. Chem. Letters, Vo. 11, pp. 2011-2015.
Philchenkov et al., 2004, "Caspases and cancer: mechanisms of inactivation and new treatment modalities", Exp. Oncol., vol. 26(2), pp. 82-97.
Raisz, L.G., 1988, "Local and systemic factors in the pathogenesis of osteoporosis," N. Engl. J. Med., vol. 318, pp. 818-828.
Ralston, S.H., 1997, "Science, Medicine and the Future: Osteoporosis," Br. Med. J., vol. 315, pp. 469-472.
Ramachandran PV, Gong B, Brown HC, 1995, "Chiral synthesis via organoboranes", J. Org. Chem., vol. 60, pp. 41-46.
Rodan, G.A., et al., 1997, "The missing bone," Cell, vol. 89, pp. 677-680.
Roodman, 2006, "Regulation of osteoclast differentiation", Ann. N. Y. Acad. Sci. , vol. 1068, pp. 100-109.
Smolen et al., 2003, "Therapeutic Strategies for Rheumatoid Arthritis", Nat. Rev. Drug Disc. , vol. 2, pp. 473-488.
Takahashi, N.; et al., 1988, "Osteoblastic cells are involved in osteoclast formation," Endocrinology, vol. 123, pp. 2600-2602.
Takasuka, M., et al., 1991, "FTIR spectral study of intramolecular hydrogen bonding in thromboxane A2 receptor antagonist S-145 and related compounds. 3. Conformation and activity of S-145 analogues", J. Med. Chem., vol. 34, pp. 1885-1891.
Tanaka et al., 2003, Signal transduction pathways regulating osteoclast differentiation and function, J. Bone Miner. Metab., vol. 21, pp. 123-133.
UK Search Report for GB 0412553.0.
UK Search Report for GB 0817207.4.
UK Search Report for GB 0817208.2.
UK Search Report for GB 705400.0.
van den Berg et al., 1999, "Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-I", Baillieres Best Pract. Res. Clin. Rheumatol., vol. 13(4), pp. 577-597.
van den Berg, 2002, "Is there a rationale for combined TNF and IL-1 blocking in arthritis?", Clin. Exp. Rheumatol. , vol. 20, pp. S21-S25.
van't Hof, R.J., et a;., 1997, "Cytokine-induced nitric oxide inhibits bone resorption by inducing apoptosis of osteoclast progenitors and suppressing osteoclast activity," J. Bone & Miner. Res., vol. 12(11), pp. 1797-1804.
Weissmann, 2006, "The pathogenesis of rheumatoid arthritis," Bull. Hosp. Jt. Dis., vol. 64, pp. 12-15.
Yasuda, H., et al, 1998, "Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro", Endocrinology, vol. 139(3), pp. 1329-1337.
Ziff, 1990, "Rheumatoid arthritis-it's present and future", J. Rheumatol., vol. 17, pp. 127-133.
Ziff, 1990, "Rheumatoid arthritis—it's present and future", J. Rheumatol., vol. 17, pp. 127-133.

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050329B1 (en) 2008-09-19 2015-06-09 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US9302984B2 (en) 2008-09-19 2016-04-05 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US9616037B2 (en) 2008-09-19 2017-04-11 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US9624167B2 (en) 2013-06-26 2017-04-18 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US9796670B2 (en) 2013-06-26 2017-10-24 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US10029979B2 (en) 2013-06-26 2018-07-24 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US10233147B2 (en) 2013-06-26 2019-03-19 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US10005733B2 (en) 2014-12-17 2018-06-26 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
US11760746B2 (en) 2018-02-16 2023-09-19 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds
US11944611B2 (en) 2018-07-16 2024-04-02 Gilead Sciences, Inc. Capsid inhibitors for the treatment of HIV
US11807625B2 (en) 2019-11-26 2023-11-07 Gilead Sciences, Inc. Capsid inhibitors for the prevention of HIV
US11787825B2 (en) 2021-12-03 2023-10-17 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection

Also Published As

Publication number Publication date
CA2736971A1 (en) 2010-03-25
EP2344449A1 (en) 2011-07-20
US20150266815A1 (en) 2015-09-24
US20150141472A1 (en) 2015-05-21
US9616037B2 (en) 2017-04-11
GB0817207D0 (en) 2008-10-29
CY1116650T1 (el) 2017-03-15
US8822507B2 (en) 2014-09-02
DK2344449T3 (en) 2015-08-17
US20130245018A1 (en) 2013-09-19
US20110172189A1 (en) 2011-07-14
US20160206578A1 (en) 2016-07-21
WO2010032009A1 (en) 2010-03-25
ES2544511T3 (es) 2015-08-31
HRP20150839T1 (hr) 2015-09-11
CA2736971C (en) 2017-06-20
US9302984B2 (en) 2016-04-05
EP2344449B1 (en) 2015-05-13
SI2344449T1 (sl) 2015-09-30
US9050329B1 (en) 2015-06-09
SMT201500218B (it) 2015-10-30
PL2344449T3 (pl) 2015-10-30
PT2344449E (pt) 2015-09-16
JP5771524B2 (ja) 2015-09-02
JP2012502964A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
US9616037B2 (en) Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US8207167B2 (en) Aryl-phenyl-sulfonamide-phenylene compounds and their use
US8524778B2 (en) Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents
US10233147B2 (en) N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamides and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamides and their therapeutic use
US20180297955A1 (en) N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
US7560597B2 (en) 2′,4′-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds and their use as therapeutic agents

Legal Events

Date Code Title Description
AS Assignment

Owner name: PIMCO 2664 LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GREIG, IAIN ROBERT;SHERIDAN, ROSE MARY;FISHER, RAYMOND;AND OTHERS;SIGNING DATES FROM 20110407 TO 20110505;REEL/FRAME:026440/0773

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8